Author: "Jutel, Marek" / Database: OpenAIRE - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Jutel, Marek"' showing total 67 results

Start Over Author "Jutel, Marek" Database OpenAIRE

67 results on '"Jutel, Marek"'

1. Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19

Author: Radzikowska, Urszula, Eljaszewicz, Andrzej, Tan, Ge, Stocker, Nino, Heider, Anja, Westermann, Patrick, Steiner, Silvio, Dreher, Anita, Wawrzyniak, Paulina, Rückert, Beate, Rodriguez-Coira, Juan, Zhakparov, Damir, Huang, Mengting, Jakiela, Bogdan, Sanak, Marek, Moniuszko, Marcin, O'Mahony, Liam, Jutel, Marek, Kebadze, Tatiana, Jackson, J David, Edwards, R Michael, Thiel, Volker, Johnston, L Sebastian, Akdis, A Cezmi, and Sokolowska, Milena
Subjects: Multidisciplinary, 630 Agriculture, General Physics and Astronomy, 630 Landwirtschaft, General Chemistry, General Biochemistry, Genetics and Molecular Biology
Abstract: Rhinoviruses and allergens, such as house dust mite are major agents responsible for asthma exacerbations. The influence of pre-existing airway inflammation on the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely unknown. We analyse mechanisms of response to viral infection in experimental in vivo rhinovirus infection in healthy controls and patients with asthma, and in in vitro experiments with house dust mite, rhinovirus and SARS-CoV-2 in human primary airway epithelium. Here, we show that rhinovirus infection in patients with asthma leads to an excessive RIG-I inflammasome activation, which diminishes its accessibility for type I/III interferon responses, leading to their early functional impairment, delayed resolution, prolonged viral clearance and unresolved inflammation in vitro and in vivo. Pre-exposure to house dust mite augments this phenomenon by inflammasome priming and auxiliary inhibition of early type I/III interferon responses. Prior infection with rhinovirus followed by SARS-CoV-2 infection augments RIG-I inflammasome activation and epithelial inflammation. Timely inhibition of the epithelial RIG-I inflammasome may lead to more efficient viral clearance and lower the burden of rhinovirus and SARS-CoV-2 infections.
Published: 2023

2. Consistent trajectories of rhinitis control and treatment in 16,177 weeks

Author: Sousa-Pinto, Bernardo, Schünemann, Holger J., Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Anto, Josep M., Klimek, Ludger, Czarlewski, Wienczyslawa, Mullol, Joaquim, Pfaar, Oliver, Bedbrook, Anna, Brussino, Luisa, Kvedariene, Violeta, Larenas-Linnemann, Désirée E., Okamoto, Yoshitaka, Ventura, Maria Teresa, Agache, Ioana, Ansotegui, Ignacio J., Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Canonica, G. Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Thomas, Cecchi, Lorenzo, Chivato, Tomas, Chu, Derek K., Cingi, Cemal, Costa, Elísio M., Cruz, Alvaro A., Del Giacco, Stefano, Devillier, Philippe, Eklund, Patrik, Fokkens, Wytske J., Gemicioglu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Khaitov, Musa, Kraxner, Helga, Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michael, Monti, Riccardo, Morais-Almeida, Mario, Mösges, Ralph, Niedoszytko, Marek, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S., Reitsma, Sietze, Rouadi, Philip W., Samolinski, Boleslaw, Sheikh, Aziz, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Vandenplas, Olivier, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, Joao A., Bousquet, Jean, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Subjects: rhinitis, real-world data, patient-reported outcomes, Immunology, Immunology and Allergy, mobile health
Abstract: Funding Information: MASK‐air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis and Uriach. Publisher Copyright: © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air® longitudinally, clustering weeks according to reported rhinitis symptoms. Methods: We analyzed MASK-air® data, assessing the weeks for which patients had answered a rhinitis daily questionnaire on all 7 days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used the latent class mixture model to assess the robustness of results. Results: We analyzed 113,239 days (16,177 complete weeks) from 2590 patients (mean age ± SD = 39.1 ± 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed a higher frequency of rhinitis co-medication, a more frequent change of medication schemes and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control. Conclusions: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms. publishersversion published
Published: 2023

3. The ARIA-MASK-air® approach

Author: Bousquet, Jean, Anto, Josep M., Sousa-Pinto, Bernardo, Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Klimek, Ludger, Pfaar, Oliver, Kuna, Piotr, Kupczyk, Maciej, Regateiro, Frederico S., Samolinski, Boleslaw, Valiulis, Arunas, Yorgancioglu, Arzu, Arnavielhe, Sylvie, Basagaña, Xavier, Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, G. Walter, Cardona, Victoria, Cecchi, Lorenzo, Chaves-Loureiro, Claudia, Costa, Elisio, Cruz, Alvaro A., Gemicioglu, Bilun, Fokkens, Wytske J., Ivancevich, Juan Carlos, Kraxner, Helga, Kvedariene, Violeta, Larenas-Linnemann, Désirée E., Laune, Daniel, Louis, Renaud, Makris, Michael, Maurer, Marcus, Melén, Erik, Micheli, Yann, Morais-Almeida, Mario, Mullol, Joaquim, Niedoszytko, Marek, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Rouadi, Philip W., Sastre, Joaquin, Scichilone, Nicola, Sheikh, Aziz, Sofiev, Mikhail, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valovirta, Erkka, Ventura, Maria Teresa, Vieira, Rafael José, Zidarn, Mihaela, Amaral, Rita, Ansotegui, Ignacio J., Bédard, Annabelle, Benveniste, Samuel, Bewick, Michael, Bindslev-Jensen, Carsten, Blain, Hubert, Bonini, Matteo, Bourret, Rodolphe, Braido, Fulvio, Carreiro-Martins, Pedro, Charpin, Denis, Cherrez-Ojeda, Ivan, Chivato, Tomas, Chu, Derek K., Cingi, Cemal, Del Giacco, Stefano, de Blay, Frédéric, Devillier, Philippe, De Vries, Govert, Doulaptsi, Maria, Doyen, Virginie, Dray, Gérard, Fontaine, Jean François, Gomez, R. Maximiliano, Hagemann, Jan, Heffler, Enrico, Hofmann, Maja, Jassem, Ewa, Jutel, Marek, Keil, Thomas, Kritikos, Vicky, Kull, Inger, Kulus, Marek, Lourenço, Olga, Mathieu-Dupas, Eve, Menditto, Enrica, Mösges, Ralph, Murray, Ruth, Nadif, Rachel, Neffen, Hugo, Nicola, Stefania, O’Hehir, Robyn, Olze, Heidi, Palamarchuk, Yuliia, Pépin, Jean Louis, Pétré, Benoit, Picard, Robert, Pitsios, Constantinos, Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Reitsma, Sietze, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romantowski, Jan, Sá-Sousa, Ana, Serpa, Faradiba S., Savouré, Marine, Shamji, Mohamed H., Sova, Milan, Sperl, Annette, Stellato, Cristiana, Todo-Bom, Ana, Tomazic, Peter Valentin, Vandenplas, Olivier, Van Eerd, Michiel, Vasankari, Tuula, Viart, Frédéric, Waserman, Susan, Fonseca, Joao A., Zuberbier, Torsten, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Comprehensive Health Research Centre (CHRC) - pólo NMS
Subjects: Pulmonary and Respiratory Medicine, rhinitis, mHealth, digital, Immunology, Immunology and Allergy, asthma, MASK-air
Abstract: Funding Information: The authors thank Ms Véronique Pretschner for submitting the paper. MASK‐air has been supported by Charité Universitätsmedizin Berlin, EU grants (EU Structural and Development Funds Languedoc Roussillon and Region PACA; POLLAR: EIT Health; Twinning: EIP on AHA; Twinning DHE: H2020; Catalyse: Horizon Europe) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis, Stallergènes‐Greer and Uriach. None for the study. ® Publisher Copyright: © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. MASK-air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma. publishersversion published
Published: 2023

4. Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19

Author: Radzikowska, Urszula, Eljaszewicz, Andrzej, Tan, Ge, Stocker, Nino, Heider, Anja, Westermann, Patrick, Steiner, Silvio, Dreher, Anita, Wawrzyniak, Paulina, Rückert, Beate, Rodriguez-Coira, Juan, Zhakparov, Damir, Huang, Mengting, Jakiela, Bogdan, Sanak, Marek, Moniuszko, Marcin, O'Mahony, Liam, Jutel, Marek, Kebadze, Tatiana, and Jackson, J. David
Abstract: Rhinoviruses and allergens, such as house dust mite are major agents responsible for asthma exacerbations. The influence of pre-existing airway inflammation on the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely unknown. We analyse mechanisms of response to viral infection in experimental in vivo rhinovirus infection in healthy controls and patients with asthma, and in in vitro experiments with house dust mite, rhinovirus and SARS-CoV-2 in human primary airway epithelium. Here, we show that rhinovirus infection in patients with asthma leads to an excessive RIG-I inflammasome activation, which diminishes its accessibility for type I/III interferon responses, leading to their early functional impairment, delayed resolution, prolonged viral clearance and unresolved inflammation in vitro and in vivo. Pre-exposure to house dust mite augments this phenomenon by inflammasome priming and auxiliary inhibition of early type I/III interferon responses. Prior infection with rhinovirus followed by SARS-CoV-2 infection augments RIG-I inflammasome activation and epithelial inflammation. Timely inhibition of the epithelial RIG-I inflammasome may lead to more efficient viral clearance and lower the burden of rhinovirus and SARS-CoV-2 infections., Nature Communications, 14 (1), ISSN:2041-1723
Published: 2023
Full Text: View/download PDF

5. Author Correction: Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19

Author: Radzikowska, Urszula, Eljaszewicz, Andrzej, Tan, Ge, Stocker, Nino, Heider, Anja, Westermann, Patrick, Steiner, Silvio, Dreher, Anita, Wawrzyniak, Paulina, Rückert, Beate, Rodriguez-Coira, Juan, Zhakparov, Damir, Huang, Mengting, Jakiela, Bogdan, Sanak, Marek, Moniuszko, Marcin, O'Mahony, Liam, Jutel, Marek, Kebadze, Tatiana, Jackson, David J, Edwards, Michael R, Thiel, Volker, Johnston, Sebastian L, Akdis, Cezmi A, and Sokolowska, Milena
Subjects: 630 Agriculture
Published: 2023
Full Text: View/download PDF

6. Rhinitis associated with asthma is distinct from rhinitis alone: TARIA‐MeDALL hypothesis

Author: Bousquet, Jean, Melén, Erik, Haahtela, Tari, Koppelman, Gerard, Togias, Alkis, Valenta, Rudolf, Akdis, Cezmi, Czarlewski, Wienczyslawa, Rothenberg, Marc, Valiulis, Arunas, Wickman, Magnus, Vichyanond, Pakit, Moniuszko, Marcin, Ėmužytė, Regina, Bush, Andrew, Chu, Derek K, Viegi, Giovanni, Wallace, Dana, Durham, Stephen, Wang, De Yun, Vandenplas, O., Just, Jocelyne, Carlsen, Karin C. Lodrup, Passalacqua, Giovanni, Williams, Siân, Linnemann, Désirée Larenas, Loureiro, Cláudia Chaves, Sagara, Hironori, Worm, Margitta, Yiallouros, Panayiotis, Yusuf, Osman, Zaitoun, Fares, Bonini, Matteo, Hrubiško, Martin, Cingi, C., Dykewicz, Mark, Zernotti, Mario, Calderon, Moises, Halpin, David M.G., Zidarn, Mihaela, Patella, Vincenzo, Sheikh, Aziz, Zuberbier, Jaron, Papadopoulos, Nikolaos, Louis, Renaud, Suppli Ulrik, Charlotte, Fonseca, João P., Zuberbier, Torsten, Anto, M. J., Costa, Elisio, Eiwegger, Thomas, Bosnic-Anticevich, Sinthia, Cruz, Alvaro, Sousa, Jaime Correia de, Louis-Philippe, Boulet, Erhola, Marina, Cardona, Victoria, Carr, Warner, Gemicioglu, Bilun, Pawankar, Ruby, Fokkens, Wytske, Calvo, Mário, Garcia-Aymerich, J., Mäkelä, Mika J., Hofmann, Maja Ann, Klimek, Ludger, Makris, Michael, Mohamed Sayed, Zeinab, Maurer, Marcus, D'Amato, G., Momas, Isabelle, Siroux, Valérie, Almeida, Mário Morais, Corrigan, Chris, Mullol, Joaquim, Montefort, Stephen, Jutel, Marek, Pham Thi, Nhan, Hossny, Elham, Akdis, Mubeccel, Pfaar, Oliver, Ventura, Maria Teresa, Regateiro, Frederico S., Bindslev-Jensen, Carsten, Ring, Johannes, Bustamante, Mariona, Pinto, Bernardo Sousa, Kaidashev, Igor, Guerra, Stefano, Standl, Marie, Sunyer, J., Keil, Thomas, Barata, Luís Taborda, Camargos, Paulo, Weiss, Scott, Naclerio, Robert, Yorgancıoglu, Arzu, Zhang, Luo, Nadeau, Kari, Abdul Latiff, Amir, Aberer, Werner, Heinrich, Joachim, Sisul, Juan, Nunes, Elizabete, Plavec, Davor, Agache, Ioana, Al-Ahmad, Mona, Serpa, Faradiba, Alobid, Isam, Kalayci, Omer, Giacco, S. Del, Fiocchi, Alessandro, Ansotegui Zubeldia, Ignacio Javier, Custovic, Adnan, Martins, Pedro Carreiro, Rouadi, Philip, Arshad, Syed Hasan, Asayag, Estrella, Bárbara, Cristina, Abdullah, Baharudin, Tomazic, Peter Valentin, Popov, T. A., Sayah, Zineb, Lkhagvaa, Battur, Nyembue Tshipukane , Dieudonne, Thomas, Mike, Bennoor, Kazi Saifuddin, Fyhrquist, Nanna Theresia, Irani, Carla, Berghea, Elena Camelia, De Blay, Frédéric, Toppila-Salmi, Sanna Katriina, Bergmann, Karl-Christian, Bernstein, D., Bewick, M., Casale, Thomas, Scheire, Sophie, Bumbacea, Roxana Silvia, Cepeda Sarabia, Alfonso, Puggioni, Francesca, Chandrasekharan, Ramanathan, Ohta, Ken, Okubo, Kimihiro, Charpin, Denis, Gomez, R Maximiliano, Chen, Y. Z., O'Hehir, Robyn, Cherrez Ojeda, Ivan, Bedbrook, Anna, To, Teresa, Devillier, Philippe, Schmid-Grendelmeier, Peter, Didier, Alain, Repka-Ramirez, María Susana, Teixeira, Maria Do Céu, Ispayeva, Zhanat, Dokic, Dejan, Quirce, Santiago, Douagui , Habib, Ivancevich, Juan Carlos, Gotua, Maia, Todo-Bom, Ana, Blain, Hubert, Guzman, Maria Antonieta, Kalyoncu, Ali Fuat, Hagemann, Jan, Buhl, Roland, Hamamah, Samir, Caraballo, Luis, Jares, Edgardo, Chivato, Tomás, Jartti, Tuomas, Jassem, Ewa, Christoff, George, Julge, Kalev, Ogulur, Ismail, Kardas, Przemyslaw, Doulaptsi, Maria, Kirenga, Bruce, Helga, Kraxner, Kull, Inger, Kulus, Marek, Daniel, Aguilar, Shamji, Mohamed, Kuna, Piotr, Nadif, Rachel, La Grutta, Stefania, Brightling, Chris, Samoliński, Bolesław, Lau, Susanne, Cordeiro, Carlos Manuel Da Silva Robalo, Solé, Dirceu, Le Thi Tuyet, Lan, Recto, Marysia, Ouedraogo, Solange, Halken, Susanne, Levin, Michael, Lipworth, Brian, Lourenço, Olga, Mahboub, Bassam, Niedoszytko, Marek, Sastre, Joaquin, Martinez‐Infante, E., Kupczyk, Maciej, Torres, María Jose, Matricardi, Paolo Maria, Cecchi, Lorenzo, Celedón, Juan C, Miculinic, Neven, Roche, Nicolas, Migueres, Nicolas, Brussino, Luisa, Florin, Mihaltan, Olze, Heidi, Savouré, Marine, Nekam, Kristof, Pali, Isabella, Okamoto, Yoshitaka, Palomares, O., Lemonnier, Nathanaël, Palosuo, Kati, Soto-Martinez, Manuel, Panaitescu, Carmen, Kvedarienė, Violeta, Panzner, P., Braido, Fulvio, Tsiligianni, Ioanna, Rodriguez-Gonzalez, Monica, Scichilone, Nicola, Canonica, Giogio Walter, Romantowski, Jan, Urrutia-Pereira, Marilyn, Filho, Nelson Augusto Rosario, Ollert, Markus W., Rottem, Menachem, Chkhartishvili, Ekaterine, Sova, Milan, Valovirta, Erkka, Mohammad, Yousser, Sperl, Annette, Spranger, Otto, Neffen, Hugo, Stelmach, Rafael, Burte, Emilie, Valentin Rostan, Marylin, Park, Hae-Sim, Van Ganse, Eric, Van Hage, Marianne, Pitsios, Constantinos, Vasankari, Tuula, and uBibliorum
Subjects: IL-33, Multimorbidity, Asthma, Toll-like receptors, Rhinitis
Abstract: Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis.
Published: 2023

7. The ARIA approach of Value-Added Medicines:as-needed treatment in allergic rhinitis

Author: Bousquet, Jean, Toumi, Mondher, Sousa-Pinto, Bernardo, Anto, Josep M, Bedbrook, Anna, Czarlewski, Wienczyslawa, Valiulis, Arunas, Ansotegui, Ignacio J, Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, G Walter, Cecchi, Lorenzo, Cherrez-Ojeda, Ivan, Chivato, Tomas, Costa, Elísio M, Cruz, Alvaro A, Del Giacco, Stefano, Fonseca, Joao A, Gemicioglu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Jutel, Marek, Kaidashev, Igor, Klimek, Ludger, Kvedariene, Violeta, Kuna, Piotr, Larenas-Linnemann, Désirée E, Lipworth, Brian, Morais-Almeida, Mario, Mullol, Joaquim, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S, Rouadi, Philip W, Samolinski, Boleslaw, Sheikh, Aziz, Taborda-Barata, Luis, Ventura, Maria Teresa, Yorgancioglu, Arzu, Zidarn, Mihaela, and Zuberbier, Torsten
Subjects: Treatment, Value-added medicine, MASK-air, Repurposing, Allergic rhinitis
Abstract: Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.
Published: 2022

8. A study using MASK-air® real-world data

Author: Sousa-Pinto, Bernardo, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Klimek, Ludger, Czarlewski, Wienczyslawa, Antó, Josep M, Pfaar, Oliver, Bedbrook, Anna, Kvedariene, Violeta, Ventura, Maria Teresa, Ansotegui, Ignacio J, Bergmann, Karl-Christian, Brussino, Luisa, Canonica, G Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Tomas, Cecchi, Lorenzo, Chivato, Tomás, Chu, Derek K, Cingi, Cemal, Costa, Elísio M, Cruz, Alvaro A, De Feo, Giulia, Devillier, Philippe, Fokkens, Wytske J, Gaga, Mina, Gemicioğlu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Larenas-Linnemann, Désirée E, Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michael, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S, Reitsma, Sietze, Rouadi, Philip W, Samolinski, Boleslaw, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Vandenplas, Olivier, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, João Almeida, Bousquet, Jean, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), Centro de Estudos de Doenças Crónicas (CEDOC), and Comprehensive Health Research Centre (CHRC) - pólo NMS
Abstract: Funding: This study was funded by ARIA. MASK-air® has been supported by EU grants (EU Structural and Development grant, POLLAR: EIT Health and Structural and Development Funds) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach. Open Access funding enabled and organized by Projekt DEAL. BACKGROUND: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. METHODS: We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy, and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ("VAS Global Symptoms") and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within one year. RESULTS: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy, and 38,315 (17.3%) under co-medication. The median "VAS Global Symptoms" was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p
Published: 2022

9. Results of a Bayesian mixed-effects model

Author: Sousa-Pinto, Bernardo, Azevedo, Luís Filipe, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Klimek, Ludger, Czarlewski, Wienczyslawa, Anto, Josep M., Bedbrook, Anna, Kvedariene, Violeta, Ventura, Maria Teresa, Ansotegui, Ignacio J., Bergmann, Karl Christian, Brussino, Luisa, Canonica, G. Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Thomas, Cecchi, Lorenzo, Chivato, Tomás, Chu, Derek K., Cingi, Cemal, Costa, Elisio M., Cruz, Alvaro A., De Feo, Giulia, Devillier, Philippe, Fokkens, Wytske J., Gaga, Mina, Gemicioğlu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Larenas-Linnemann, Désirée E., Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michaël, Monti, Riccardo, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S., Reitsma, Sietze, Rouadi, Philip W., Samolinski, Boleslaw, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, João Almeida, Bousquet, Jean, Pfaar, Oliver, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Comprehensive Health Research Centre (CHRC) - pólo NMS
Subjects: Pulmonary and Respiratory Medicine, allergic rhinitis, patient-reported outcomes, Immunology, Immunology and Allergy, real-life data analysis, immunotherapy, mobile health
Abstract: Funding Information: MASK-air has been supported by Charit? Universit?tsmedizin Berlin, EU Grants (EU Structural and Development Funds, POLLAR: EIT Health POLLAR, EIT Health Twinning) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach. Open access funding enabled and organized by Projekt DEAL. Publisher Copyright: © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness. publishersversion published
Published: 2022

10. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Claus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink Wagner, Antje, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo M., Spertini, François, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O´Mahony, Liam, Knol, Edward, del Giacco, Stefano, Chivato, Tomás, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek
Subjects: Titel, SARS-CoV-2, Medizin, Immunology and Allergy, Omalizumab, Benralizumab, Dupilumab, Reslizumab, Covid-19, Telemedizin, Mepolizumab
Published: 2020

11. Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma

Author: Vogelberg,Christian, BrÃ¼ggenjÃ¼rgen,Bernd, Richter,Hartmut, and Jutel,Marek
Subjects: allergic rhinitis, Patient Preference and Adherence, subcutaneous immunotherapy, tree pollen, otorhinolaryngologic diseases, adherence, grass pollen, asthma, real-world evidence, sublingual immunotherapy, respiratory tract diseases, Original Research
Abstract: Christian Vogelberg,1 Bernd Brüggenjürgen,2 Hartmut Richter,3 Marek Jutel4,5 1Department of Pediatric Pneumology and Allergology, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany; 2Institute for Health Economics, Steinbeis University Berlin, Berlin, Germany; 3Epidemiology, IQVIA, Frankfurt am Main, Germany; 4All-MED Medical Research Institute, Warsaw, Poland; 5Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, PolandCorrespondence: Christian VogelbergUniversity Hospital Carl Gustav Carus Dresden, Fetscherstrasse 74, Dresden 01307, GermanyTel +49 351 458-5699Fax +49 351 458-4334Email Christian.Vogelberg@uniklinikum-dresden.dePurpose: Allergen immunotherapy (AIT), when continued for 3 years, is the only disease-modifying treatment for AR and asthma. Adherence is a key to ensure effectiveness, and poor adherence is a contraindication for AIT. The objective of this study was to evaluate real-world adherence to AIT with subcutaneousimmunotherapy (SCIT) and sublingualimmunotherapy (SLIT) preparations in patients allergic to grass or tree pollen. The impact of AIT on the consumption of asthma and rhinitis medication was also analyzed.Patients and Methods: In this retrospective cohort analysis of a German longitudinal prescription database, the adherence of a grass and tree pollen allergoid was examined and compared to two sublingual AIT tablets/drops. Patients receiving grass or tree allergen-specific immunotherapy prescriptions were compared with non-AIT patients receiving symptomatic allergic rhinitis (AR) and asthma prescriptions. The study endpoints included therapy adherence, AR progression, and asthma progression. Multivariate regression analyses were used to estimate the effects of SCIT or SLIT, adjusting for variables related to demographics and prescriptions.Results: SCIT adherence was 60.1– 61.8% at 2 years and 35.0– 37.5% at 3 years for the two allergens. SLIT adherence was distinctly lower (29.5– 36.5% and 9.6– 18.2%, respectively). Adherence in children was higher compared to adolescents or adults. All products were highly efficacious at reducing symptomatic AR medication consumption. SCIT also reduced asthma medication use for both allergens, whereas for SLIT these results were significant only for grasses but not trees.Conclusion: Subcutaneous AIT in a real-world setting achieved significantly higher adherence rates compared to sublingual administration. SCIT reduced the use of rhinitis and asthma medication significantly for both allergens, while SLIT reduced the use of rhinitis medication for both allergens and the use of asthma medication for grasses only.Keywords: adherence, real-world evidence, allergic rhinitis, asthma, grass pollen, tree pollen, subcutaneous immunotherapy, sublingual immunotherapy
Published: 2020

12. The Allergic Rhinitis and its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis

Author: Bousquet, Jean J., Toumi, Mondher, Sousa-Pinto, Bernardo, Antó, Josep María, Bedbrook, Anna, Czarlewski, Wienczyslawa, Valiulis, Arūnas, Ansótegui, Ignacio Javier, Bosnic-Anticevich, Sinthia Zrinka, Brussino, Luisa, Canonica, Walter G., Cecchi, Lorenzo, Chérrez, Ivan, Chivato, Tomas, Costa, Elísio Sbardellotto Mariano Da, Cruz, Álvaro Augusto, Giacco, Stefano R. del, Fonseca, Joao A., Gemicioǧlu, Bilun, Haahtela, Tari M.K., Ivancevich, J.C., Jutel, Marek, Kaidashev, I. Petrovich, Klimek, Ludger, Kvedariene, Violeta, Kuna, P.B., Larenas-Linnemann, Désirée E.S., Lipworth, Brian Jonathon, Morais-Almeida, Mário A., Mullol, Joaquim, Papadopoulos, N.G., Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico Soares, Rouadi, Philip W., Samoliński, Bolesław Krzysztof, Sheikh, Aziz, Taborda-Barata, Luís Manuel, Ventura, M.T., Yorgancıoğlu, Arzu A., Zidarn, Mihaela, Zuberbier, Torsten, and Publica
Subjects: Treatment, Value-added medicine, MASK-air, Repurposing, Allergic rhinitis
Abstract: Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.
Published: 2022

13. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions : A GA(2)LEN position paper

Author: Zuberbier, Torsten, Doerr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Begin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J., Custovic, Adnan, Darsow, Ulf, Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Galvin, Audrey Dunn, Ebisawa, Motohiro, Fernandez-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, van Wijk, Roy Gerth, Gotua, Maia, Grimshaw, Kate, Gruenhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, John, Swen Malte, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak-Wegrzyn, Anna, Nwaru, Bright, Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G., Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Woehrl, Stefan, Wong, Gary W. K., Zhao, Zuotao, Worm, Margitta, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, and University of Helsinki
Subjects: food allergy, Respiratory Medicine and Allergy, PEANUT ALLERGY, CHILDREN, COWS MILK, ORAL IMMUNOTHERAPY, DIAGNOSIS, SESAME, EXERCISE-INDUCED ANAPHYLAXIS, nutrition, 3121 General medicine, internal medicine and other clinical medicine, ADOLESCENTS, TESTS, anaphylaxis, CHALLENGE, Lungmedicin och allergi
Abstract: Background Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as "may contain traces of" is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin. Methods MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results. Results In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy, and sesame seeds. Conclusion Based on the literature studied for this review, it can be stated that cross-contamination of the 14 major food allergens below 0.5 mg/100 g is likely not to endanger most food allergic patients when a standard portion of food is consumed. We propose to use the statement "this product contains the named allergens in the list of ingredients, it may contain traces of other contaminations (to be named, e.g. nut) at concentrations less than 0.5 mg per 100 g of this product" for a voluntary declaration on processed food packages. This level of avoidance of cross-contaminations can be achieved technically for most processed foods, and the statement would be a clear and helpful message to the consumers. However, it is clearly acknowledged that a voluntary declaration is only a first step to a legally binding solution. For this, further research on threshold levels is encouraged.
Published: 2022

14. Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA 2 LEN consensus

Author: Hagemann, Jan, Onorato, Gabrielle L, Jutel, Marek, Akdis, Cezmi A, et al, and University of Zurich
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published: 2021

15. COVID‐19 vaccines ‐ the way forward

Author: Klimek, Ludger, Agache, Ioana, Cooke, Emer, Jutel, Marek, Akdis, Cezmi A, O'Hehir, Robyn, University of Zurich, and Klimek, Ludger
Subjects: Licensure, 2403 Immunology, 2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Immunology, COVID-19, 610 Medicine & health, Harmonization, Public relations, Antibodies, Viral, Clinical trial, Vaccine administration, Editorial, 10183 Swiss Institute of Allergy and Asthma Research, COVID‐19, Social system, Pandemic, 2723 Immunology and Allergy, Immunology and Allergy, Humans, business
Abstract: In a health crisis of the calibre of the COVID‐19 pandemic, the development of effective and safe vaccines is considered the most powerful measure to save lives and minimise the tremendous negative impact on health, social systems and global economics. Vaccines must be evaluated and approved by the appropriate regulatory and/or health authorities. To date, the worldwide regulatory landscape for vaccines is very broad. Bringing COVID‐19 vaccines to the market, the authorities followed at least 51 different pathways, offering various types of accelerated vaccine approval. 1 China, Russia and the United Arab Emirates initiated the vaccine administration before the conclusion of clinical trials. This patchwork of approval processes has revived a long‐standing question, how to better facilitate harmonization in vaccine regulation and whether a harmonized approval process would make the vaccine development procedures more effective, quicker, broadly accessible and administered by the whole world and even less expensive. In this issue, experts from the Paul‐Ehrlich Institute, the regulatory institution for vaccine development in Germany, describe the regulatory procedures, concepts and requirements that are applied to guide and promote the accelerated development and licensure of safe and efficacious COVID‐19 vaccines in Europe.2
Published: 2021

16. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

Author: Bousquet, Jean, Pfaar, Oliver, Agache, Ioana, Bedbrook, Anna, Akdis, Cezmi A, Canonica, Giorgio Walter, Chivato, Tomas, Al-Ahmad, Mona, Rasib, A. H. Abdul, Ansotegui, Ignacio J, Bachert, Claus, Soto-Martinez, Manuel, Laune, Daniel, Casale, Tomas, Levin, Michael, Larenas-Linnemann, Désirée, Samolinski, Boleslaw, Lodrup Carlsen, Karin C, O'Mahony, Liam, Lombardi, Carlo, Riggioni, Carmen, Hossny, Elham, Barata, Luís Taborda, Lourenço, Olga, Devillier, Philippe, Mahboub, Bassam, Malling, Hans-Jørgen, Sheikh, Aziz, Manning, Patrick, Passalacqua, Giovanni, Marshall, Gailen D, Sanchez-Borges, Mario, Toppila-Salmi, Sanna, Melén, Erik, Fokkens, Wytske J, Meltzer, Eli O, Miculinic, Neven, Soto-Quiros, Manuel, Milenkovic, Branislava, Roberts, Graham, Ohta, Ken, Scichilone, Nicola, Moin, Mostafa, Odemyr, Mikaëla, Montefort, Stephen, Almeida, Mário Morais, Bom, Ana Todo, Mortz, Charlotte G, Serpa, Faradiba S, Patella, Vincenzo, Sova, Milan, Mösges, Ralph, Mullol, Joaquim, Namazova Baranova, Leyla, Tsiligianni, Ioanna, Neffen, Hugo, Bjermer, Leif, Rodriguez-Gonzales, Monica, Torres, Maria J, Okamoto, Yoshitaka, Okubo, Kimi, Pajno, Giovanni B, Baharuddin, Abdullah, Cecchi, Lorenzo, Sastre, Joaquin, Untersmayr, Eva, Pawankar, Ruby, Pham-Thi, Nhân, Plavec, Davor, Cardona, Victoria, Dokic, Dejan, Sisul, Juan Carlos, Rosario, Nelson, Rottem, Menachem, Rouadi, Philip W, Del Giacco, Stefano, Fonseca, Joao A, Schwarze, Jürgen, Scadding, Glenis K, Shamji, Mohamed H, Schmid-Grendelmeier, Peter, Niedoszytko, Marek, Valentin-Rostan, Marylin, Sofiev, Mikhail, Solé, Dirceu, Sooronbaev, Talant, Palkonen, Susanna, Urrutia-Pereira, Marilyn, Skypala, Isabel, Suppli-Ulrik, Charlotte, Bonini, Matteo, Popov, Todor A, Tomazic, Peter-Valentin, Valero, Antonio, Cepeda Sarabia, Alfonso M, Ryan, Dermot, Bosnic-Anticevich, Sinthia, Valiulis, Arunas, Durham, Stephen L, Schünemann, Holger, Kalayci, Omer, Valovirta, Erkka, Panzner, Petr, Vandenplas, Olivier, Ventura, Maria Teresa, Gotua, Maia, Vichyanond, Pakit, Chkhartishvili, Ekaterine, Wagenmann, Martin, Fontaine, Jean-François, Kull, Inger, Wallace, Dana, Recto, Marysia, Walusiak-Skorupa, Jolanta, Wang, De Yun, Hrubiško, Martin, Waserman, Susan, Ebisawa, Motohiro, Bosse, Isabelle, Grisle, Ineta, Wong, Gary Wk, Bindslev-Jensen, Carsten, Yorgancioglu, Arzu, Yusuf, Osman M, Khaitov, Musa, Zernotti, Mario, Gawlik, Radoslaw, Chu, Derek K, Irani, Carla, Zhang, Luo, Zidarn, Mihaela, Zuberbier, Torsten, Kuna, Piotr, Jutel, Marek, Guzmán, Maria Antonieta, El-Gamal, Yehia, Klimek, Ludger, Brough, Helen A, Brussino, Luisa, Calderon, Moises A, Caraballo, Luis, O'Hehir, Robyn E, Gelincik, Asli, Kvedariene, Violeta, Cirule, Ieva, Cruz, Alvaro A, Czarlewski, Wienczyslawa, Nekam, Kristof, Papadopoulos, Nikolaos G., Haahtela, Tari, Emuzyte, Regina, Gamkrelidze, Amiran, Fauquert, Jean Luc, Palomares, Oscar, Regateiro, Frederico S, Ivancevich, Juan Carlos, Gemicioglu, Bilun, Gereda, Jose E, Gerth van Wijk, Roy, Bergmann, Karl-Christian, Knol, Edward, Halken, Susanne, Heffler, Enrico, Hoffmann-Sommergruber, Karin, Martins, Pedro Carreiro, Kritikos, Vicky, Ispayeva, Zhanat, Julge, Kaja, Kaidashev, Igor, Demoly, Pascal, Kowalski, Marek, Kraxner, Helga, Ollert, Markus, Fiocchi, Alessandro, Lauerma, Antti, Lau, Susanne, Park, Hae-Sim, Gomez, R Maximiliano, Comprehensive Health Research Centre (CHRC) - pólo NMS, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), uBibliorum, Bousquet J., Pfaar O., Agache I., Bedbrook A., Akdis C.A., Canonica G.W., Chivato T., Al-Ahmad M., Abdul Latiff A.H., Ansotegui I.J., Bachert C., Baharuddin A., Bergmann K.-C., Bindslev-Jensen C., Bjermer L., Bonini M., Bosnic-Anticevich S., Bosse I., Brough H.A., Brussino L., Calderon M.A., Caraballo L., Cardona V., Carreiro-Martins P., Casale T., Cecchi L., Cepeda Sarabia A.M., Chkhartishvili E., Chu D.K., Cirule I., Cruz A.A., Czarlewski W., del Giacco S., Demoly P., Devillier P., Dokic D., Durham S.L., Ebisawa M., El-Gamal✝ Y., Emuzyte R., Gamkrelidze A., Fauquert J.L., Fiocchi A., Fokkens W.J., Fonseca J.A., Fontaine J.-F., Gawlik R., Gelincik A., Gemicioglu B., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gotua M., Grisle I., Guzman M.-A., Haahtela T., Halken S., Heffler E., Hoffmann-Sommergruber K., Hossny E., Hrubisko M., Irani C., Ivancevich J.C., Ispayeva Z., Julge K., Kaidashev I., Kalayci O., Khaitov M., Klimek L., Knol E., Kowalski M.L., Kraxner H., Kull I., Kuna P., Kvedariene V., Kritikos V., Lauerma A., Lau S., Laune D., Levin M., Larenas-Linnemann D.E., Lodrup Carlsen K.C., Lombardi C., Lourenco O.M., Mahboub B., Malling H.-J., Manning P., Marshall G.D., Melen E., Meltzer E.O., Miculinic N., Milenkovic B., Moin M., Montefort S., Morais-Almeida M., Mortz C.G., Mosges R., Mullol J., Namazova Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Ollert M., O'Mahony L., Ohta K., Okamoto Y., Okubo K., Pajno G.B., Palomares O., Palkonen S., Panzner P., G Papadopoulos N., Park H.-S., Passalacqua G., Patella V., Pawankar R., Pham-Thi N., Plavec D., Popov T.A., Recto M., Regateiro F.S., Riggioni C., Roberts G., Rodriguez-Gonzales M., Rosario N., Rottem M., Rouadi P.W., Ryan D., Samolinski B., Sanchez-Borges✝ M., Serpa F.S., Sastre J., Scadding G.K., Shamji M.H., Schmid-Grendelmeier P., Schunemann H.J., Sheikh A., Scichilone N., Sisul J.C., Sofiev M., Sole D., Sooronbaev T., Soto-Martinez M., Soto-Quiros M., Sova M., Schwarze J., Skypala I., Suppli-Ulrik C., Taborda-Barata L., Todo-Bom A., Torres M.J., Valentin-Rostan M., Tomazic P.-V., Valero A., Toppila-Salmi S., Tsiligianni I., Untersmayr E., Urrutia-Pereira M., Valiulis A., Valovirta E., Vandenplas O., Ventura M.T., Vichyanond P., Wagenmann M., Wallace D., Walusiak-Skorupa J., Wang D.Y., Waserman S., Wong G.W.K., Yorgancioglu A., Yusuf O.M., Zernotti M., Zhang L., Zidarn M., Zuberbier T., Jutel M., HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Department of Pathology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Philipps Universität Marburg = Philipps University of Marburg, Transilvania University of Brasov, Universität Zürich [Zürich] = University of Zurich (UZH), Humanitas University [Milan] (Hunimed), Universidad San Pablo CEU, Kuwait University, Al-Rashed Allergy Center [Kuwait City], Pantai Hospital [Kuala Lumpur], Hospital Quirónsalud Bizkaia [Bilbao], Ghent University Hospital, Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Sun Yat-Sen University [Guangzhou] (SYSU), Universiti Sains Malaysia (USM), Humboldt University Of Berlin, Berlin Institute of Health (BIH), Odense University Hospital (OUH), Skane University Hospital [Lund], Fondazione Policlinico Universitario Agostino Gemelli IRCCS, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Woolcock Institute of Medical Research [Sydney], The University of Sydney, Guy's and St Thomas' Hospital [London], King‘s College London, Università degli studi di Torino = University of Turin (UNITO), University of Cartagena, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], Universidad Simon Bolivar (USB), David Tvildiani Medical University (DTMU), McMaster University [Hamilton, Ontario], Children's Clinical University Hospital [Riga, Latvia] (CCUH), Universidade Federal da Bahia (UFBA), Università degli Studi di Cagliari = University of Cagliari (UniCa), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Foch [Suresnes], Sagamihara National Hospital [Kanagawa, Japan], Université Ain Shams, Vilnius University [Vilnius], CHU Clermont-Ferrand, IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Universidade do Porto = University of Porto, Silesian Medical University, Katowice, Poland, Cerrahpasa Faculty of Medicine, Istanbul University, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Universidad de Chile = University of Chile [Santiago] (UCHILE), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Medizinische Universität Wien = Medical University of Vienna, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Tartu University Hospital [Tartu, Estonia], Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Hacettepe University = Hacettepe Üniversitesi, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Siriraj Hospital, Mahidol University, Mahidol University [Bangkok], Nova Southeastern University (NSU), Nofer Institute of Occupational Medicine (NIOM), National University of Singapore (NUS), Yong Loo Lin School of Medicine [Singapore], The Chinese University of Hong Kong [Hong Kong], Manisa Celal Bayar University, Universidad Nacional de Villa María, Universidad Católica de Córdoba, Beijing Tongren Hospital, Herrada, Anthony, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie
Subjects: Pulmonary and Respiratory Medicine, precision medicine, education, Immunology, Review, Settore MED/10 - Malattie Dell'Apparato Respiratorio, immune system diseases, HDE ALER, allergic rhinitis, asthma, immunotherapy, Medicine and Health Sciences, Immunology and Allergy, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, ComputingMilieux_MISCELLANEOUS, Rhinitis, RC581-607, respiratory tract diseases, 3121 General medicine, internal medicine and other clinical medicine, Immunologic diseases. Allergy, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, allergic rhinitis, asthma, immunotherapy, precision medicine
Abstract: Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, scibase, advisory role in Sanofi/Regeneron, grants from Glakso Smith‐Kline, advisory role in scibase. Funding Information: MJTreports grants from European Commission, SEAIC, ISCIII, personal fees from Diater laboratory, Leti laboratory, Aimmune Therapeutics. Funding Information: LK reports grants and personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi, grants from Stallergenes, Quintiles, ASIT biotech, grants from ALK Abelló, Lofarma, AstraZeneca, GSK, Inmunotk, personal fees from Allergy Therapeut., HAL Allergie, Cassella med; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. Funding Information: DPreports grants and personal fees from GlaxoSmithKline, personal fees from Menarini, Pliva, Belupo, AbbVie, Novartis, MSD, Chiesi, Revenio, personal fees and non‐financial support from Boehringer Ingelheim, non‐financial support from Philips. Funding Information: OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, Inmunotek S.L., personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS. Copyright: Copyright 2021 Elsevier B.V., All rights reserved. publishersversion published
Published: 2021

17. The European Curriculum for Additional Qualification Allergology A Position Paper by Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA) in cooperation with European Academy for Allergology and Clinical Immunology (EAACI) and Allergology Section of European Union of Medical Specialists (UEMS)

Author: Muelleneisen, Norbert, Klimek, Ludger, Worm, Margitta, Merk, Hans, Rabe, Uta, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Bergmann, Karl-Christian A., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Matricardi, Paolo, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Van Wijk, Roy Gerth, Eguiluz-Gracia, Ibon, Gayraud, Jacques, Gutermuth, Jan, Heffler, Enrico, Popov, Todor A., Schmid-Grendelmeier, Peter, Tomazic, Peter, V, Tsilochristou, Olympia, Del Giacco, Stefano, Zuberbier, Torsten, Jutel, Marek, Artificial Intelligence supported Modelling in clinical Sciences, Gerontology, Skin function and permeability, and Dermatology
Subjects: The European Curriculum for Additional Qualification Allergolog, Dermatology
Published: 2021

18. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

Author: Incorvaia, Cristoforo, Al‐Ahmad, Mona, Ansotegui, Ignacio J, Arasi, Stefania, Bachert, Claus, Bos, Catherine, Bousquet, Jean, Bozek, Andrzéj, Caimmi, Davide, Calderón, Moises A, Casale, Thomas, Custovic, Adnan, De Blay, Frédéric, Demoly, Pascal, Devillier, Philippe, Didier, Alain, Fiocchi, Alessandro, Fox, Adam T, Gevaert, Philippe, Gomez, Maximiliano, Heffler, Enrico, Ilina, Natalia, Irani, Carla, Jutel, Marek, Karagiannis, Efstrathios, Klimek, Ludger, Kuna, Piotr, O'Hehir, Robin, Kurbacheva, Oxana, Matricardi, Paolo M, et al, Schmid-Grendelmeier, Peter, University of Zurich, and Heffler, Enrico
Subjects: 2403 Immunology, Immunology, 2723 Immunology and Allergy, 10177 Dermatology Clinic, Immunology and Allergy, 610 Medicine & health
Published: 2021

19. ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)

Author: Bousquet, Jean, Jutel, Marek, Akdis, Cezmi A, Klimek, Ludger, Pfaar, Oliver, et al, Akdis, Mübeccel, University of Zurich, and Bousquet, Jean
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published: 2021

20. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

Author: Bousquet, Jean, Pfaar, Oliver, Agache, Ioana, Bedbrook, Anna, Akdis, Cezmi A.., Canonica, G. Walter, Chivato, Tomas, Al-Ahmad, Mona, Abdul Latiff, Amir H., Ansotegui, Ignacio J., Bachert, Claus, Baharuddin, Abdullah, Bergmann, Karl-Christian, Bindslev-Jensen, Carsten, Bjermer, Leif, Bonini, Matteo, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Brough, Helen A., Brussino, Luisa, Calderon, Moises A., Caraballo, Luis, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Thomas, Cecchi, Lorenzo, Cepeda Sarabia, Alfonso M., Chkhartishvili, Ekaterine, Chu, Derek K., Cirule, Ieva, Cruz, Alvaro A., Czarlewski, Wienczyslawa, Del Giacco, Stefano, Demoly, Pascal, Devillier, Philippe, Dokic, Dejan, Durham, Stephen L., Ebisawa, Motohiro, El-Gamal✝, Yehia, Emuzyte, Regina, Gamkrelidze, Amiran, Fauquert, Jean Luc, Fiocchi, Alessandro, Fokkens, Wytske J., Fonseca, Joao A., Fontaine, Jean-François, Gawlik, Radoslaw, Gelincik, Asli, Gemicioglu, Bilun, Gereda, Jose E., Gerth van Wijk, Roy, Gomez, R. Maximiliano, Gotua, Maia, Grisle, Ineta, Guzmán, Maria-Antonieta, Haahtela, Tari, Halken, Susanne, Heffler, Enrico, Hoffmann-Sommergruber, Karin, Hossny, Elham, Hrubiško, Martin, Irani, Carla, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Julge, Kaja, Kaidashev, Igor, Kalayci, Omer, Khaitov, Musa, Klimek, Ludger, Knol, Edward, Kowalski, Marek L., Kraxner, Helga, Kull, Inger, Kuna, Piotr, Kvedariene, Violeta, Kritikos, Vicky, Lauerma, Antti, Lau, Susanne, Laune, Daniel, Levin, Michael, Larenas-Linnemann, Desiree E., Lodrup Carlsen, Karin C., Lombardi, Carlo, Lourenço, Olga M., Mahboub, Bassam, Malling, Hans-Jørgen, Manning, Patrick, Marshall, Gailen D., Melén, Erik, Meltzer, Eli O., Miculinic, Neven, Milenkovic, Branislava, Moin, Mostafa, Montefort, Stephen, Morais-Almeida, Mario, Mortz, Charlotte G., Mösges, Ralph, Mullol, Joaquim, Namazova Baranova, Leyla, Neffen, Hugo, Nekam, Kristof, Niedoszytko, Marek, Odemyr, Mikaëla, O'Hehir, Robyn E., Ollert, Markus, O'Mahony, Liam, Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimi, Pajno, Giovanni B., Palomares, Oscar, Palkonen, Susanna, Panzner, Petr, G. Papadopoulos, Nikolaos, Park, Hae-Sim, Passalacqua, Giovanni, Patella, Vincenzo, Pawankar, Ruby, Pham-Thi, Nhân, Plavec, Davor, Popov, Todor A., Recto, Marysia, Regateiro, Frederico S., Riggioni, Carmen, Roberts, Graham, Rodriguez-Gonzales, Monica, Rosario, Nelson, Rottem, Menachem, Rouadi, Philip W., Ryan, Dermot, Samolinski, Boleslaw, Sanchez-Borges✝, Mario, Serpa, Faradiba S., Sastre, Joaquin, Scadding, Glenis K., Shamji, Mohamed H., Schmid-Grendelmeier, Peter, Schünemann, Holger J., Sheikh, Aziz, Scichilone, Nicola, Sisul, Juan Carlos, Sofiev, Mikhail, Solé, Dirceu, Sooronbaev, Talant, Soto-Martinez, Manuel, Soto-Quiros, Manuel, Sova, Milan, Schwarze, Jürgen, Skypala, Isabel, Suppli-Ulrik, Charlotte, Taborda-Barata, Luis, Todo-Bom, Ana, Torres, Maria J., Valentin-Rostan, Marylin, Tomazic, Peter-Valentin, Valero, Antonio, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Untersmayr, Eva, Urrutia-Pereira, Marilyn, Valiulis, Arunas, Valovirta, Erkka, Vandenplas, Olivier, Ventura, Maria Teresa, Vichyanond, Pakit, Wagenmann, Martin, Wallace, Dana, Walusiak-Skorupa, Jolanta, Wang, De Yun, Waserman, Susan, Wong, Gary W. K., Yorgancioglu, Arzu, Yusuf, Osman M., Zernotti, Mario, Zhang, Luo, Zidarn, Mihaela, Zuberbier, Torsten, Jutel, Marek, and Universitat Autònoma de Barcelona
Subjects: Precision medicine, Immunotherapy, Allergic rhinitis, Asthma
Published: 2021

21. Climate change: a call to action for the united nations [Editorial]

Author: Nadeau, Kari C., Agache, Ioana, Jutel, Marek, Annesi Maesano, Isabella, Akdis, Mübeccel, Sampath, Vanitha, D'Amato, Gennaro, Cecchi, Lorenzo, Traidl-Hoffmann, Claudia, and Akdis, Cezmi A.
Subjects: ddc:610
Published: 2021

22. ARIA digital anamorphosis: digital transformation of health and care in airway diseases from research to practice

Author: Bousquet, Jean, Anto, Josep M., Bachert, Claus, Haahtela, Tari, Zuberbier, Torsten, Czarlewski, Wienczyslawa, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Walter Canonica, G, Cardona, Victoria, ElisioCosta, Cruz, Alvaro A, Erhola, Marina, Fokkens, Wytske J, Fonseca, Joao A, Illario, Maddalena, CarlosIvancevich, Juan, Jutel, Marek, Klimek, Ludger, PiotrKuna, Kvedariene, Violeta, Le, Ltt, Larenas-Linnemann, Desiree, Laune, Daniel, Lourenço, Olga M, Melén, Eric, Mullol, Joaquim, Niedoszytko, Marek, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikos G, Patella, Vincenzo, Pfaar, Oliver, Pham-Thi, Nhân, Rolland, Christine, Samolinski, Boleslaw, Sheikh, Aziz, Sofiev, Mikhail, SuppliUlrik, Charlotte, Todo-Bom, Ana, Tomazic, Peter V, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valiulis, Arunas, Valovirta, Erkka, Ventura, Maria-Teresa, Walker, Samantha, Williams, Sian, Price, David, and Roberts, Graham
Abstract: Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis.It strengthens the ARIA change management strategy in the prevention and managementof airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.
Published: 2021

23. Digital transformation of health and care in airway diseases from research to practice

Author: Bousquet, Jean, Anto, Josep M., Bachert, Claus, Haahtela, Tari, Zuberbier, Torsten, Czarlewski, Wienczyslawa, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Walter Canonica, G., Cardona, Victoria, Costa, Elisio, Cruz, Alvaro A., Erhola, Marina, Fokkens, Wytske J., Fonseca, Joao A., Illario, Maddalena, Ivancevich, Juan Carlos, Jutel, Marek, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Le, L. T.T., Larenas-Linnemann, Désirée E., Laune, Daniel, Lourenço, Olga M., Melén, Erik, Mullol, Joaquim, Niedoszytko, Marek, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikos G., Patella, Vincenzo, Pfaar, Oliver, Pham-Thi, Nhân, Rolland, Christine, Samolinski, Boleslaw, Sheikh, Aziz, Sofiev, Mikhail, Suppli Ulrik, Charlotte, Todo-Bom, Ana, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valiulis, Arunas, Valovirta, Erkka, Ventura, Maria Teresa, Walker, Samantha, Williams, Sian, Yorgancioglu, Arzu, Agache, Ioana, Akdis, Cezmi A., Almeida, Rute, Ansotegui, Ignacio J., Annesi-Maesano, Isabella, Arnavielhe, Sylvie, Basagaña, Xavier, D. Bateman, Eric, Bédard, Annabelle, Bedolla-Barajas, Martin, Becker, Sven, Bennoor, Kazi S., Benveniste, Samuel, Bergmann, Karl C., Bewick, Michael, Bialek, Slawomir, E. Billo, Nils, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Bonini, Matteo, Bonniaud, Philippe, Bosse, Isabelle, Bouchard, Jacques, Boulet, Louis Philippe, Bourret, Rodolphe, Boussery, Koen, Braido, Fluvio, Briedis, Vitalis, Briggs, Andrew, Brightling, Christopher E., Brozek, Jan, Brusselle, Guy, Brussino, Luisa, Buhl, Roland, Buonaiuto, Roland, Calderon, Moises A., Camargos, Paulo, Camuzat, Thierry, Caraballo, Luis, Carriazo, Ana Maria, Carr, Warner, Cartier, Christine, Casale, Thomas, Cecchi, Lorenzo, Cepeda Sarabia, Alfonso M., H. Chavannes, Niels, Chkhartishvili, Ekaterine, Chu, Derek K., Cingi, Cemal, Correia de Sousa, Jaime, Costa, David J., Courbis, Anne Lise, Custovic, Adnan, Cvetkosvki, Biljana, D'Amato, Gennaro, da Silva, Jane, Dantas, Carina, Dokic, Dejan, Dauvilliers, Yves, De Feo, Giulia, De Vries, Govert, Devillier, Philippe, Di Capua, Stefania, Dray, Gerard, Dubakiene, Ruta, Durham, Stephen R., Dykewicz, Marc, Ebisawa, Motohiro, Gaga, Mina, El-Gamal, Yehia, Heffler, Enrico, Emuzyte, Regina, Farrell, John, Fauquert, Jean Luc, Fiocchi, Alessandro, Fink-Wagner, Antje, Fontaine, Jean François, Fuentes Perez, José M., Gemicioğlu, Bilun, Gamkrelidze, Amiran, Garcia-Aymerich, Judith, Gevaert, Philippe, Gomez, René Maximiliano, González Diaz, Sandra, Gotua, Maia, Guldemond, Nick A., Guzmán, Maria Antonieta, Hajjam, Jawad, Huerta Villalobos, Yunuen R., Humbert, Marc, Iaccarino, Guido, Ierodiakonou, Despo, Iinuma, Tomohisa, Jassem, Ewa, Joos, Guy, Jung, Ki Suck, Kaidashev, Igor, Kalayci, Omer, Kardas, Przemyslaw, Keil, Thomas, Khaitov, Musa, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Kouznetsov, Rostislav, Kowalski, Marek L., Kritikos, Vicky, Kull, Inger, La Grutta, Stefania, Leonardini, Lisa, Ljungberg, Henrik, Lieberman, Philip, Lipworth, Brian, Lodrup Carlsen, Karin C., Lopes-Pereira, Catarina, Loureiro, Claudia C., Louis, Renaud, Mair, Alpana, Mahboub, Bassam, Makris, Michaël, Malva, Joao, Manning, Patrick, Marshall, Gailen D., Masjedi, Mohamed R., Maspero, Jorge F., Carreiro-Martins, Pedro, Makela, Mika, Mathieu-Dupas, Eve, Maurer, Marcus, De Manuel Keenoy, Esteban, Melo-Gomes, Elisabete, Meltzer, Eli O., Menditto, Enrica, Mercier, Jacques, Micheli, Yann, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Mitsias, Dimitirios I., Moda, Giuliana, Mogica-Martinez, Maria Dolores, Mohammad, Yousser, Montefort, Steve, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralph, Münter, Lars, Muraro, Antonella, Murray, Ruth, Naclerio, Robert, Napoli, Luigi, Namazova-Baranova, Leyla, Neffen, Hugo, Nekam, Kristoff, Neou, Angelo, Nordlund, Björn, Novellino, Ettore, Nyembue, Dieudonné, O'Hehir, Robyn, Ohta, Ken, Okubo, Kimi, Onorato, Gabrielle L., Orlando, Valentina, Ouedraogo, Solange, Palamarchuk, Julia, Pali-Schöll, Isabella, Panzner, Peter, Park, Hae Sim, Passalacqua, Gianni, Pépin, Jean Louis, Paulino, Ema, Pawankar, Ruby, Phillips, Jim, Picard, Robert, Pinnock, Hilary, Plavec, Davor, Popov, Todor A., Portejoie, Fabienne, Price, David, Prokopakis, Emmanuel P., Psarros, Fotis, Pugin, Benoit, Puggioni, Francesca, Quinones-Delgado, Pablo, Raciborski, Filip, Rajabian-Söderlund, Rojin, Regateiro, Frederico S., Reitsma, Sietze, Rivero-Yeverino, Daniela, Roberts, Graham, Roche, Nicolas, Rodriguez-Zagal, Erendira, Roller-Wirnsberger, Regina E., Rosario, Nelson, Romano, Antonino, Rottem, Menachem, Ryan, Dermot, Salimäki, Johanna, Sanchez-Borges, Mario M., Sastre, Joaquin, Scadding, Glenis K., Scheire, Sophie, Schmid-Grendelmeier, Peter, Schünemann, Holger J., Sarquis Serpa, Faradiba, Shamji, Mohamed, Sisul, Juan Carlos, Solé, Dirceu, Somekh, David, Sooronbaev, Talant, Sova, Milan, Spertini, François, Spranger, Otto, Stellato, Cristiana, Stelmach, Rafael, Thibaudon, Michel, To, Teresa, Toumi, Mondher, Usmani, Omar, Valero, Antonio A., Valenta, Rudolph, Valentin-Rostan, Marylin, Pereira, Marilyn Urrutia, van der Kleij, Rianne, Van Eerd, Michiel, Vandenplas, Olivier, Vasankari, Tuula, Vaz Carneiro, Antonio, Vezzani, Giorgio, Viart, Frédéric, Viegi, Giovanni, Wallace, Dana, Wagenmann, Martin, Wang, De Yun, Waserman, Susan, Wickman, Magnus, Williams, Dennis M., Wong, Gary, Wroczynski, Piotr, Yiallouros, Panayiotis K., Yusuf, Osman M., Zar, Heather J., Zeng, Stéphane, Zernotti, Mario E., Zhang, Luo, Shan Zhong, Nan, Zidarn, Mihaela, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Subjects: ARIA, rhinitis, CARAT, MASK, Immunology, Immunology and Allergy, asthma, digital transformation of health and care
Abstract: Funding: MA reports personal fees from POCI-01-0145-FEDER-029130 mINSPIRERS—mHealth to measure and improve adherence to medication in chronic obstructive respiratory diseases—generalization and evaluation of gamification, peer support and advanced image processing technologies from ERDF (European Regional Development Fund) funded by the COMPETE2020 and by National Funds through FCT (Fundação para a Ciência e a Tecnologia)… Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed. publishersversion published
Published: 2021

24. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

Author: Bousquet, Jean Anto, Josep M. Bachert, Claus Haahtela, Tari and Zuberbier, Torsten Czarlewski, Wienczyslawa Bedbrook, Anna and Bosnic-Anticevich, Sinthia Walter Canonica, G. Cardona, Victoria Costa, Elisio Cruz, Alvaro A. Erhola, Marina and Fokkens, Wytske J. Fonseca, Joao A. Illario, Maddalena and Ivancevich, Juan-Carlos Jutel, Marek Klimek, Ludger Kuna, Piotr Kvedariene, Violeta Le, L. T. T. Larenas-Linnemann, Desiree E. Laune, Daniel Lourenco, Olga M. Melen, Erik and Mullol, Joaquim Niedoszytko, Marek Odemyr, Mikaela Okamoto, Yoshitaka Papadopoulos, Nikos G. Patella, Vincenzo Pfaar, Oliver Pham-Thi, Nhan Rolland, Christine Samolinski, Boleslaw Sheikh, Aziz Sofiev, Mikhail Suppli Ulrik, Charlotte Todo-Bom, Ana Tomazic, Peter-Valentin and Toppila-Salmi, Sanna Tsiligianni, Ioanna Valiulis, Arunas and Valovirta, Erkka Ventura, Maria-Teresa Walker, Samantha and Williams, Sian Yorgancioglu, Arzu Agache, Ioana Akdis, Cezmi A. Almeida, Rute Ansotegui, Ignacio J. Annesi-Maesano, Isabella Arnavielhe, Sylvie Basagana, Xavier D. Bateman, Eric Bedard, Annabelle Bedolla-Barajas, Martin Becker, Sven and Bennoor, Kazi S. Benveniste, Samuel Bergmann, Karl C. and Bewick, Michael Bialek, Slawomir E. Billo, Nils and Bindslev-Jensen, Carsten Bjermer, Leif Blain, Hubert Bonini, Matteo Bonniaud, Philippe Bosse, Isabelle Bouchard, Jacques and Boulet, Louis-Philippe Bourret, Rodolphe Boussery, Koen and Braido, Fluvio Briedis, Vitalis Briggs, Andrew Brightling, Christopher E. Brozek, Jan Brusselle, Guy Brussino, Luisa and Buhl, Roland Buonaiuto, Roland Calderon, Moises A. and Camargos, Paulo Camuzat, Thierry Caraballo, Luis Carriazo, Ana-Maria Carr, Warner Cartier, Christine Casale, Thomas and Cecchi, Lorenzo Cepeda Sarabia, Alfonso M. H. Chavannes, Niels and Chkhartishvili, Ekaterine Chu, Derek K. Cingi, Cemal and Correia de Sousa, Jaime Costa, David J. Courbis, Anne-Lise and Custovic, Adnan Cvetkosvki, Biljana D'Amato, Gennaro da Silva, Jane Dantas, Carina Dokic, Dejan Dauvilliers, Yves and De Feo, Giulia De Vries, Govert Devillier, Philippe Di Capua, Stefania Dray, Gerard Dubakiene, Ruta Durham, Stephen R. Dykewicz, Marc Ebisawa, Motohiro Gaga, Mina El-Gamal, Yehia Heffler, Enrico Emuzyte, Regina Farrell, John and Fauquert, Jean-Luc Fiocchi, Alessandro Fink-Wagner, Antje and Fontaine, Jean-Francois Fuentes Perez, Jose M. Gemicioglu, Bilun and Gamkrelidze, Amiran Garcia-Aymerich, Judith Gevaert, Philippe Gomez, Rene Maximiliano Gonzalez Diaz, Sandra and Gotua, Maia Guldemond, Nick A. Guzman, Maria-Antonieta and Hajjam, Jawad Huerta Villalobos, Yunuen R. Humbert, Marc and Iaccarino, Guido Ierodiakonou, Despo Iinuma, Tomohisa and Jassem, Ewa Joos, Guy Jung, Ki-Suck Kaidashev, Igor and Kalayci, Omer Kardas, Przemyslaw Keil, Thomas Khaitov, Musa and Khaltaev, Nikolai Kleine-Tebbe, Jorg Kouznetsov, Rostislav and Kowalski, Marek L. Kritikos, Vicky Kull, Inger La Grutta, Stefania Leonardini, Lisa Ljungberg, Henrik and Lieberman, Philip Lipworth, Brian Lodrup Carlsen, Karin C. and Lopes-Pereira, Catarina Loureiro, Claudia C. Louis, Renaud and Mair, Alpana Mahboub, Bassam Makris, Michael Malva, Joao and Manning, Patrick Marshall, Gailen D. Masjedi, Mohamed R. and Maspero, Jorge F. Carreiro-Martins, Pedro Makela, Mika and Mathieu-Dupas, Eve Maurer, Marcus De Manuel Keenoy, Esteban and Melo-Gomes, Elisabete Meltzer, Eli O. Menditto, Enrica and Mercier, Jacques Micheli, Yann Miculinic, Neven Mihaltan, Florin Milenkovic, Branislava Mitsias, Dimitirios I. Moda, Giuliana Mogica-Martinez, Maria-Dolores Mohammad, Yousser and Montefort, Steve Monti, Ricardo Morais-Almeida, Mario and Mosges, Ralph Munter, Lars Muraro, Antonella Murray, Ruth and Naclerio, Robert Napoli, Luigi Namazova-Baranova, Leyla and Neffen, Hugo Nekam, Kristoff Neou, Angelo Nordlund, Bjorn and Novellino, Ettore Nyembue, Dieudonne O'Hehir, Robyn and Ohta, Ken Okubo, Kimi Onorato, Gabrielle L. Orlando, Valentina Ouedraogo, Solange Palamarchuk, Julia Pali-Scholl, Isabella Panzner, Peter Park, Hae-Sim Passalacqua, Gianni and Pepin, Jean-Louis Paulino, Ema Pawankar, Ruby Phillips, Jim Picard, Robert Pinnock, Hilary Plavec, Davor Popov, Todor A. Portejoie, Fabienne Price, David Prokopakis, Emmanuel P. Psarros, Fotis Pugin, Benoit Puggioni, Francesca and Quinones-Delgado, Pablo Raciborski, Filip and Rajabian-Soderlund, Rojin Regateiro, Frederico S. Reitsma, Sietze Rivero-Yeverino, Daniela Roberts, Graham Roche, Nicolas Rodriguez-Zagal, Erendira Rolland, Christine and Roller-Wirnsberger, Regina E. Rosario, Nelson Romano, Antonino and Rottem, Menachem Ryan, Dermot Salimaki, Johanna and Sanchez-Borges, Mario M. Sastre, Joaquin Scadding, Glenis K. and Scheire, Sophie Schmid-Grendelmeier, Peter Schunemann, Holger J. and Sarquis Serpa, Faradiba Shamji, Mohamed Sisul, Juan-Carlos and Sofiev, Mikhail Sole, Dirceu Somekh, David Sooronbaev, Talant Sova, Milan Spertini Spranger, Otto Stellato, Cristiana Stelmach, Rafael Thibaudon, Michel To, Teresa and Toumi, Mondher Usmani, Omar Valero, Antonio A. Valenta, Rudolph Valentin-Rostan, Marylin Pereira, Marilyn Urrutia and van der Kleij, Rianne Van Eerd, Michiel Vandenplas, Olivier and Vasankari, Tuula Vaz Carneiro, Antonio Vezzani, Giorgio and Viart, Frederic Viegi, Giovanni Wallace, Dana Wagenmann, Martin Wang, De Yun Waserman, Susan Wickman, Magnus and Williams, Dennis M. Wong, Gary Wroczynski, Piotr Yiallouros, Panayiotis K. Yusuf, Osman M. Zar, Heather J. Zeng, Stephane and Zernotti, Mario E. Zhang, Luo Shan Zhong, Nan Zidarn, Mihaela
Abstract: Digital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validated digital tools. Using the MASK digital tool and the CARAT online enhanced clinical framework, solutions for practical steps of digital enhancement of care are proposed.
Published: 2021

25. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice

Author: Bousquet, Jean, Anto, Josep M, Bachert, Claus, Haahtela, Tari, Zuberbier, Torsten, Czarlewski, Wienczyslawa, Bedbrook, Anna, Bosnic‐Anticevich, Sinthia, Walter Canonica, G, Cardona, Victoria, Costa, Elisio, Cruz, Alvaro A, Erhola, Marina, Fokkens, Wytske J, Fonseca, Joao A, Illario, Maddalena, Ivancevich, Juan‐Carlos, Jutel, Marek, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Le, L T T, Larenas‐Linnemann, Désirée E, Laune, Daniel, Lourenço, Olga M, Melén, Erik, Mullol, Joaquim, Niedoszytko, Marek, Odemyr, Mikaëla, Okamoto, Yoshitaka, et al, University of Zurich, and Bousquet, Jean
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, 10177 Dermatology Clinic, Immunology and Allergy, 610 Medicine & health
Published: 2021

26. Alergie na jady owadów u dzieci [w: Alergologia]

Author: Jutel, Marek and Cichocka-Jarosz, Ewa
Published: 2021

27. Das europäische Curriculum für die Zusatzbezeichnung Allergologie. Ein Positionspapier des Ärzteverbandes Deutscher Allergologen (AeDA)A, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)B und der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C in Kooperation mit der Europäischen Akademie für Allergologie und klinische Immunologie (EAACI)D und der Sektion Allergologie der Europäischen Union Medizinischer Spezialisten (UEMS)E

Author: Muelleneisen, Norbert, Klimek, Ludger, Worm, Margitta, Merk, Hans, Rabe, Uta, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Bergmann, Karl-Christian A., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Matricardi, Paolo, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Van Wijk, Roy Gerth, Eguiluz-Gracia, Ibon, Gayraud, Jacques, Gutermuth, Jan, Heffler, Enrico, Popov, Todor A., Schmid-Grendelmeier, Peter, Tomazic, Peter V., Tsilochristou, Olympia, Del Giacco, Stefano, Zuberbier, Torsten, and Jutel, Marek
Subjects: Political science, Immunology and Allergy, Humanities
Abstract: Hintergrund: Die Vision der europaischen allergologischen Gesellschaften ist es, die Ausbildung zum Allergologen in Europa zu vereinheitlichen und prinzipiell den Facharzt fur Allergologie zu fordern und zu fordern. In den meisten europaischen Landern gibt es bereits den Facharzt fur Allergologie. In Deutschland gibt es leider nur eine Zusatzbezeichnung Allergologie. Methoden: Um nun auch fur Lander mit lediglich einer Zusatzbezeichnung fur Allergologie eine Vorlage zu erstellen, hat die European Academy of Allergy and Clinical Immunology (EAACI) in Kooperation mit der Union Europeenne des Medecins Specialistes (UEMS) ein Curriculum fur eine Zusatzbezeichnung erstellt und veroffentlicht. Im Folgenden wird dieses europaische Positionspapier in deutscher Ubersetzung und in Anpassung an die deutschen Verhaltnisse vorgestellt. Die beteiligten Autoren reprasentieren die deutschen und die europaischen, allergologischen Fachgesellschaften. Ergebnisse: Dieses Curriculum soll den Mindeststandard der Ausbildung zum Allergologen in Deutschland beschreiben und die theoretischen Kenntnisse, Fahigkeiten, Kompetenzen sowie die Anforderungen an Ausbilder und Ausbildungsinstitutionen benennen. Schlussfolgerung: Ohne einen vollen Facharzt fur Allergologie mussen die Subspezialisten in der Allergologie zwingend mit anderen Fachgruppen kooperieren, Kompetenzen teilen und eine gemeinsame Sprache entwickeln. Die Harmonisierung der Ausbildung ist der einzige Weg, um dies zu erreichen. Fur die Zusatzbezeichnung 18 Monate Weiterbildung und fur den Facharzt funf Jahre Weiterbildung: das ist der europaische Weg. Die Deutschen Allergologen verlieren sonst den Anschluss an die europaische Entwicklung und senken die Qualitat der Ausbildung zum Allergologen gefahrlich ab.
Published: 2021

28. Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement

Author: Bousquet, Jean, Akdis, Cezmi A, Jutel, Marek, Bachert, Claus, Klimek, Ludger, et al, University of Zurich, and Bousquet, Jean
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published: 2020

29. EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network

Author: Shamji, Mohamed H, Akdis, Cezmi A, Barber, Domingo, Canonica, Walter, Chivato, Tomás, del Giacco, Stefano, Hoffman‐Sommergruber, Karin, Jutel, Marek, Knol, Edward, Ollert, Markus, O'Mahony, Liam, Palomares, Oscar, Sastre, Joaquin, Schwarze, Jürgen, Smolinska, Sylwia, Vieths, Stefan, Agache, Ioana, University of Zurich, and Shamji, Mohamed H
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published: 2020

30. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement

Author: Klimek, Ludger, Jutel, Marek, Akdis, Cezmi, Bousquet, Jean, Akdis, Mübeccel, Bachert, Claus, et al, University of Zurich, and Klimek, Ludger
Subjects: 2403 Immunology, 10183 Swiss Institute of Allergy and Asthma Research, Immunology, 2723 Immunology and Allergy, Immunology and Allergy, 610 Medicine & health
Published: 2020

31. Correction to 'ARIA guideline 2019: treatment of allergic rhinitis in the German health system' (Allergo Journal International, (2019), 28, 7, (255-276), 10.1007/s40629-019-00110-9)

Author: Klimek, Ludger, Bachert, Claus, Pfaar, Oliver, Becker, Sven, Bieber, Thomas, Brehler, Randolf, Buhl, Roland, Casper, Ingrid, Chaker, Adam, Czech, Wolfgang, Fischer, J. rg, Fuchs, Thomas, Gerstlauer, Michael, Hörmann, Karl, Jakob, Thilo, Jung, Kirsten, Kopp, Matthias V., Mahler, Vera, Merk, Hans, Mülleneisen, Norbert, Nemat, Katja, Rabe, Uta, Ring, Johannes, Saloga, Joachim, Schlenter, Wolfgang, Schmidt-Weber, Carsten, Seyfarth, Holger, Sperl, Annette, Spindler, Thomas, Staubach, Petra, Strieth, Sebastian, Treudler, Regina, Vogelberg, Christian, Wallrafen, Andrea, Wehrmann, Wolfgang, Wrede, Holger, Zuberbier, Torsten, Bedbrook, Anna, Canonica, Giorgio W., Cardona, Victoria, Casale, Thomas B., Czarlewski, Wienczylawa, Fokkens, Wytske J., Hamelmann, Eckard, Hellings, Peter W., Jutel, Marek, Larenas-Linnemann, D. sirée, Mullol, Joaquim, Papadopoulos, Nikolaos G., Toppila-Salmi, Sanna, Werfel, Thomas, Bousquet, Jean, Ear, Nose and Throat, and AII - Inflammatory diseases
Abstract: Correction to: Allergo J Int 2019 https://doi.org/10.1007/s40629-019-00110-9 Affiliation and disclaimer have been misrepresented and are hereby corrected: Vera Mahler: Affiliation: Med. Faculty, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Germany. Disclaimer: The views expressed in this.
Published: 2020

32. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma

Author: Agache, Ioana, Rocha, Claudio, Beltran, Jessica, Song, Yang, Posso, Margarita, Solà, Ivan, Alonso‐coello, Pablo, Akdis, Cezmi, Akdis, Mubeccel, Canonica, Walter, Casale, Thomas, Chivato, Tomas, Corren, Jonathan, Del Giacco, Stefano, Eiwegger, Thomas, Firinu, Davide, Gern, James E., Hamelmann, Eckard, Hanania, Nicola, Mäkelä, Mika, Martín, Irene Hernández, Nair, Parameswaran, O’mahony, Liam, Papadopoulos, Nikolaos G., Papi, Alberto, Park, Hae‐sim, Pérez De Llano, Luis, Quirce, Santiago, Sastre, Joaquin, Shamji, Mohamed, Schwarze, Jurgen, Canelo‐aybar, Carlos, Palomares, Oscar, and Jutel, Marek
Abstract: Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes.Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) versus standard of care for patients with uncontrolled severe allergic asthma. Pubmed, EMBASE and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma‐related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE.All three biologicals reduced with high certainty the annualised asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 (95% CI 0.50−0.81); dupilumab IRR 0.58 (95%CI 0.47−0.73); omalizumab IRR 0.56 (95%CI 0.42−0.73). Benralizumab and dupilumab improved asthma control with high certainty and omalizumab with moderate certainty, however none reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high certainty. Benralizumab and omalizumab showed an increase in drug‐related adverse events (AEs) with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. There was high certainty that in children 6‐12 years old omalizumab decreased the annualised exacerbation rate [IRR 0.57 (95%CI 0.45‐0.72)], improved QoL [relative risk 1.43 (95%CI 1.12 ‐1.83)], reduced ICS [mean difference (MD) ‐0.45 (95% CI ‐0.58 to ‐0.32)] and rescue medication use [ MD ‐0.41 (95%CI ‐0.66 to ‐0.15)].
Published: 2020

33. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma

Author: Agache, Ioana, Beltran, Jessica, Akdis, Cezmi, Akdis, Mubeccel, Canelo-Aybar, Carlos, Canonica, Walter, Casale, Thomas, Chivato, Tomas, Corren, Jonathan, Del Giacco, Stefano, Eiwegger, Thomas, Firinu, Davide, Gern, James E., Hamelmann, Eckard, Hanania, Nicola, Mäkelä, Mika, Martín, Irene Hernández, Nair, Parameswaran, O'Mahony, Liam, Papadopoulos, Nikolaos G., Papi, Alberto, Park, Hae-Sim, Pérez de Llano, Luis, Posso, Margarita, Rocha, Claudio, Quirce, Santiago, Sastre, Joaquin, Shamji, Mohamed, Song, Yang, Steiner, Corinna, Schwarze, Jurgen, Alonso-Coello, Pablo, Palomares, Oscar, and Jutel, Marek
Subjects: Exacerbations, safety, Severe asthma, biologicals, efficacy, severe-eosinophilic-asthma, Benralizumab, Omalizumab, Dupilumab, Reslizumab, Eosinophilic asthma, cost-effectiveness, Mepolizumab
Abstract: Five biologicals have been approved for severe eosinophilic asthma, a well-recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to standard of care for severe eosinophilic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated for each of the biologicals. The risk of bias and the certainty of the evidence were assessed using GRADE. 19 RCTs (three RCTs for benralizumab, three RCTs for dupilumab, three RCTs for mepolizumab, five RCTs for omalizumab and five RCTs for reslizumab), including subjects 12 to 75 years old (except for omalizumab including also subjects 6-11 years old), ranging from 12 to 56 weeks were evaluated. All biologicals reduce exacerbation rates with high certainty of evidence: benralizumab incidence rate ratio (IRR) 0.53 (95% CI 0.39 to 0.72), dupilumab (IRR) 0.43 (95% CI 0.32 to 0.59), mepolizumab IRR 0.49 (95% CI 0.38 to 0.66), omalizumab (IRR) 0.56 (95% CI 0.40 to 0.77) and reslizumab (IRR) 0.46 (95% CI 0.37 to 0.58). Benralizumab, dupilumab and mepolizumab reduce the daily dose of oral corticosteroids (OCS) with high certainty of evidence. All evaluated biologicals probably improve asthma control, QoL and FEV1, without reaching the minimal important difference (moderate certainty). Benralizumab, mepolizumab and reslizumab slightly increase drug-related adverse events (AE) and drug-related serious AE (low to very low certainty of evidence). The incremental cost-effectiveness ratio per quality-adjusted life year value is above the willingness to pay threshold for all biologicals (moderate certainty). Potential savings are driven by decrease in hospitalizations, emergency and primary care visits. There is high certainty that all approved biologicals reduce the rate of severe asthma exacerbations and for benralizumab, dupilumab and mepolizumab for reducing OCS. There is moderate certainty for improving asthma control, QoL, FEV1. More data on long-term safety are needed together with more efficacy data in the paediatric population.
Published: 2020

34. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

Author: Klimek, Ludger, Pfaar, Dr O., Worm, Margitta M., Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus W., Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana O., Bavbek, S., Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, A., Vogelberg, Christian, Firinu, Davide, Kauppi, P., Kolios, Antonios G.A., Kothari, Akash, Matucci, Andrea, Palomares, Óscar, Szépfalusi, Zsolt, Hötzenecker, Wolfram, Rosenkranz, A. R., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, Thomas, Kleine-Tebbe, Jörg, Lau, S., Maurer, Marcus, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus Friedrich, Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, Kirsten, Schlenter, Wolfgang W., Ring, Johannnes, Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent Pierre, Schmid-Grendelmeier, Peter D., Idzko, Marco, Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin M., Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, François R., Schwarze, Jürgen, O'Mahony, Liam, Knol, Edward Frank, del Giacco, Stefano R., Chivato Pérez, T., Bousquet, Jean J., Zuberbier, Thorsten, Akdis, Cezmi A., Jutel, Marek, MACVIA-France, Montpellier, Centre de recherche en épidémiologie et santé des populations (CESP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Subjects: SARS-CoV-2, [SDV]Life Sciences [q-bio], Benralizumab, Omalizumab, Dupilumab, Reslizumab, Covid-19, ComputingMilieux_MISCELLANEOUS, Mepolizumab, Telemedicine
Abstract: International audience
Published: 2020

35. Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHCG and the European Academy of Allergy and Clinical Immunology (EAACI)H

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, Petra, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert, Nemat, Katja, Czech, Wofgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Akdis, Cezmi, Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo, Spertin, FranÇois, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean, and Zuberbier, Torsten
Subjects: 610 Medicine & health
Abstract: No abstract available.
Published: 2020
Full Text: View/download PDF

36. Allergen immunotherapy in the current COVID-19 pandemic - A position paper of the AeDA, ARIA, EAACI, DGAKI and GPA

Author: Klimek, Ludger, Pfaar, Dr O., Worm, Margitta M., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Mar, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, P., Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, Kirsten, Schlenter, Wolfgang W., Ring, Johannnes, Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Akdis, Cezmi A., Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter D., Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin, Taube, Christian, Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean J., Zuberbier, Torsten, Rheinische Friedrich-Wilhelms-Universität Bonn, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: SLIT, [SDV]Life Sciences [q-bio], COVID-19, Antiviral immunity, SCIT, ComputingMilieux_MISCELLANEOUS, Allergen immunotherapy
Abstract: International audience
Published: 2020

37. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemie

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thohomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szepfalusi, Zsolt, Pohl, Wolfgang, Hoetzenecker, Wolfram, Rosenkranz, Alexander R., Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Joerg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Moesges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus F., Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ringa, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Muelleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje-H, Horak, Fritz, Woehrl, Stefan, Niederberger-Leppin, Verena, Pali-Schoell, Isabella, Pohlg, Wolfgang, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Muebeccel, Matricardi, Paolo M., Spertini, Francois, Khaltaev, Nikolai, Michel, Jean-Pierre, Nicod, Laurent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Juergen, O'Mahony, Liam, Knol, Edward F., del Giacco, Stefano, Chivato Perez, Tomas, Bousquet, Jean, Zuberbier, Torsten, Akdis, Cezmi, and Jutel, Marek
Published: 2020

38. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)

Author: Pfaar, Oliver, Klimek, Ludger, Worm, Margitta M., Bergmann, Karl Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen T.M., Darsow, Ulf G., Keil, T., Kleine-Tebbe, Jörg, Lau, S., Maurer, Marcus, Merk, Hans Friedrich, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Stute, P., Rabe, K., Rabe, Uta, Vogelmeier, Claus Franz, Biedermann, Tilo M., Jung, K., Schlenter, Wolfgang W., Ring, J., Chaker, Adam M., Wehrmann, Wolfgang, Becker, Sven, Mülleneisen, Norbert K., Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolph B.S., Fuchs, Thomas, Tomazic, Peter Valentin, Aberer, Werner, Fink-Wagner, Antjie Henriette, Horak, Friedrich, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Pohl, Wolfgang, Roller-Wirnsberger, Regina Elisabeth, Spranger, Otto, Valenta, Rudolf, Akdis, Mübeccel, Akdis, Cezmi A., Hoffmann-Sommergruber, Karin, Jutel, Marek, Matricardi, Paolo Maria, Spertini, François, Khaltaev, Nikolaï G., Michel, Jean Pierre, Nicod, Laurent Pierre, Schmid-Grendelmeier, Peter D., Hamelmann, E., Jakob, Thilo, Werfel, Thomas Andreas, Wagenmann, Martin M., Taube, C., Gerstlauer, Michael, Vogelberg, Christian, Bousquet, Jean J., Zuberbier, Thorsten, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), FMC VIA LR, 371, avenue Doyen-Gaston-Giraud, 34295 Montpellier cedex 5, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), and Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)
Subjects: [SHS.LANGUE]Humanities and Social Sciences/Linguistics, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2020

39. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic:Position paper of Ärzteverband Deutscher Allergologen (AeDA)A, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)B, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)D, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)E, Österreichische Gesellschaft für Pneumologie (ÖGP)F in co-operation with the German, Austrian, and Swiss ARIA groupsG, and the European Academy of Allergy and Clinical Immunology (EAACI)

Author: Klimek, Ludger, Pfaar, Oliver, Worm, Margitta, Eiwegger, Thomas, Hagemann, Jan, Ollert, Markus, Untersmayr, Eva, Hoffmann-Sommergruber, Karin, Vultaggio, Alessandra, Agache, Ioana, Bavbek, Sevim, Bossios, Apostolos, Casper, Ingrid, Chan, Susan, Chatzipetrou, Alexia, Vogelberg, Christian, Firinu, Davide, Kauppi, Paula, Kolios, Antonios, Kothari, Akash, Matucci, Andrea, Palomares, Oscar, Szépfalusi, Zsolt, Pohl, Wolfgang, Hötzenecker, Wolfram, Rosenkranz, Alexander, Bergmann, Karl-Christian, Bieber, Thomas, Buhl, Roland, Buters, Jeroen, Darsow, Ulf, Keil, Thomas, Kleine-Tebbe, Jörg, Lau, Susanne, Maurer, Marcus, Merk, Hans, Mösges, Ralph, Saloga, Joachim, Staubach, Petra, Jappe, Uta, Rabe, Klaus, Rabe, Uta, Vogelmeier, Claus, Biedermann, Tilo, Jung, Kirsten, Schlenter, Wolfgang, Ring, Johannes, Chaker, Adam, Wehrmann, Wolfgang, Becker, Sven, Freudelsperger, Laura, Mülleneisen, Norbert, Nemat, Katja, Czech, Wolfgang, Wrede, Holger, Brehler, Randolf, Fuchs, Thomas, Tomazic, Peter-Valentin, Aberer, Werner, Fink-Wagner, Antje-Henriette, Horak, Fritz, Wöhrl, Stefan, Niederberger-Leppin, Verena, Pali-Schöll, Isabella, Roller-Wirnsberger, Regina, Spranger, Otto, Valenta, Rudolf, Akdis, Mübecell, Matricardi, Paolo, Spertini, François, Khaltaev, Nicolai, Michel, Jean-Pierre, Nicod, Larent, Schmid-Grendelmeier, Peter, Idzko, Marco, Hamelmann, Eckard, Jakob, Thilo, Werfel, Thomas, Wagenmann, Martin, Taube, Christian, Jensen-Jarolim, Erika, Korn, Stephanie, Hentges, Francois, Schwarze, Jürgen, O Mahony, Liam, Knol, Edward, Del Giacco, Stefano, Chivato Pérez, Tomás, Bousquet, Jean, Bedbrook, Anna, Zuberbier, Torsten, Akdis, Cezmi, Jutel, Marek, Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Philipps Universität Marburg, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], The Hospital for sick children [Toronto] (SickKids), University of Toronto, Johannes Gutenberg - Universität Mainz (JGU), Luxembourg Institute of Health (LIH), University of Southern Denmark (SDU), Medizinische Universität Wien = Medical University of Vienna, Careggi University Hospital [Florence, Italie], Transylvania University, Ankara University School of Medicine [Turkey], Karolinska University Hospital [Stockholm], Karolinska Institutet [Stockholm], University hospital of Zurich [Zurich], Universität Zürich [Zürich] = University of Zurich (UZH), Guy's and St Thomas' Hospital [London], King‘s College London, National Technical University of Athens [Athens] (NTUA), University General Hospital ' Attikon ' [Athens, Greece], University of Athens Medical School [Athens], Universitätsklinikum Carl Gustav Carus Dresden, University of Cagliari, Harvard Medical School [Boston] (HMS), Österreichische Forschungsförderungsgesellschaft, Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Kepler University Hospital, Medizinische Universität Graz, Universitätsklinikum Bonn (UKB), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Helmholtz-Zentrum München (HZM), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), University of Würzburg = Universität Würzburg, Allergie- & Asthma-Zentrum Berlin Westend, Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany] (UKA), RWTH Aachen University, Universität zu Köln, Clinical Research International Ltd [Hamburg, Germany] (CRI), University Medical Center [Mainz], Universität zu Lübeck [Lübeck], German Research Center for Environmental Health - Helmholtz Center München (GmbH), Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Asthma und Allergiezentrum [Leverkusen], Universitätsklinikum Münster [Munster, Germany], University of Göttingen - Georg-August-Universität Göttingen, Universität Wien, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), University of Geneva [Switzerland], Universitätsspital Zürich (USZ), Universität Bielefeld = Bielefeld University, Justus-Liebig-Universität Gießen (JLU), Medizinische Hochschule Hannover (MHH), Universitatsklinikum Dusseldorf, Dusseldorf Germany, Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Centre Hospitalier de Luxembourg [Luxembourg] (CHL), University of Edinburgh, APC Microbiome Ireland, University College Cork (UCC), University Medical Center [Utrecht], Universita degli Studi di Cagliari [Cagliari], University of San Pablo, Humboldt-Universität zu Berlin, Wroclaw Medical University [Wrocław, Pologne], and Technische Universität München [München] (TUM)
Subjects: benralizumab, SARS-CoV-2, COVID-19, mepolizumab, Benralizumab, Omalizumab, Dupilumab, reslizumab, Telemedicine, dupilumab, omalizumab, telemedicine, Reslizumab, Covid-19, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Mepolizumab
Abstract: International audience; Background: Since the beginning of the COVID-19 pandemic, the treatment of patients with allergic and atopy-associated diseases has faced major challenges. Recommendations for "social distancing" and the fear of patients becoming infected during a visit to a medical facility have led to a drastic decrease in personal doctor-patient contacts. This affects both acute care and treatment of the chronically ill. The immune response after SARS-CoV-2 infection is so far only insufficiently understood and could be altered in a favorable or unfavorable way by therapy with monoclonal antibodies. There is currently no evidence for an increased risk of a severe COVID-19 course in allergic patients. Many patients are under ongoing therapy with biologicals that inhibit type 2 immune responses via various mechanisms. There is uncertainty about possible immunological interactions and potential risks of these biologicals in the case of an infection with SARS-CoV-2.Materials and methods: A selective literature search was carried out in PubMed, Livivo, and the internet to cover the past 10 years (May 2010 - April 2020). Additionally, the current German-language publications were analyzed. Based on these data, the present position paper provides recommendations for the biological treatment of patients with allergic and atopy-associated diseases during the COVID-19 pandemic.Results: In order to maintain in-office consultation services, a safe treatment environment must be created that is adapted to the pandemic situation. To date, there is a lack of reliable study data on the care for patients with complex respiratory, atopic, and allergic diseases in times of an imminent infection risk from SARS-CoV-2. Type-2-dominant immune reactions, as they are frequently seen in allergic patients, could influence various phases of COVID-19, e.g., by slowing down the immune reactions. Theoretically, this could have an unfavorable effect in the early phase of a SARS-Cov-2 infection, but also a positive effect during a cytokine storm in the later phase of severe courses. However, since there is currently no evidence for this, all data from patients treated with a biological directed against type 2 immune reactions who develop COVID-19 should be collected in registries, and their disease courses documented in order to be able to provide experience-based instructions in the future.Conclusion: The use of biologicals for the treatment of bronchial asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and spontaneous urticaria should be continued as usual in patients without suspected infection or proven SARS-CoV-2 infection. If available, it is recommended to prefer a formulation for self-application and to offer telemedical monitoring. Treatment should aim at the best possible control of difficult-to-control allergic and atopic diseases using adequate rescue and add-on therapy and should avoid the need for systemic glucocorticosteroids. If SARS-CoV-2 infection is proven or reasonably suspected, the therapy should be determined by weighing the benefits and risks individually for the patient in question, and the patient should be involved in the decision-making. It should be kept in mind that the potential effects of biologicals on the immune response in COVID-19 are currently not known. Telemedical offers are particularly desirable for the acute consultation needs of suitable patients.
Published: 2020

40. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases: Review

Author: Schünemann, Holger J., Yiallouros, Panayiotis K., Bousquet, J. Jean, Togias, Alkis, Erhola, Marina, Hellings, Peter W., Zuberbier, Torsten, Agache, Ioana, Ansotegui, Ignacio J., Anto, Josep M., Bachert, Claus, Becker, Sven, Bedolla-Barajas, Martin, Bewick, Michael, Bosnic-Anticevich, Sinthia, Bosse, Isabelle, Boulet, Louis P., Bourrez, Jean Marc, Brusselle, Guy, Chavannes, Niels, Costa, Elisio, Cruz, Alvaro A., Czarlewski, Wienczyslawa, Fokkens, Wytske J., Fonseca, Joao A., Gaga, Mina, Haahtela, Tari, Illario, Maddalena, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Le, L. T. T., Larenas-Linnemann, Desiree, Laune, Daniel, Lourenço, Olga M., Menditto, Enrica, Mullol, Joaquin, Okamoto, Yashitaka, Papadopoulos, Nikos, Pham-Thi, Nhân, Picard, Robert, Pinnock, Hilary, Roche, Nicolas, Roller-Wirnsberger, Regina E., Rolland, Christine, Samolinski, Boleslaw, Sheikh, Aziz, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valiulis, Arunas, Valovirta, Erkka, Vasankari, Tuula, Ventura, Maria-Teresa, Walker, Samantha, Williams, Sian, Akdis, Cezmi A., Annesi-Maesano, Isabella, Arnavielhe, Sylvie, Basagana, Xavier, Bateman, Eric, Bedbrook, Anna, Bennoor, K. S., Benveniste, Samuel, Bergmann, Karl C., Bialek, Slawomir, Billo, Nils, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Bonini, Mateo, Bonniaud, Philippe, Bouchard, Jacques, Briedis, Vitalis, Brightling, Christofer E., Brozek, Jan, Buhl, Roland, Buonaiuto, Roland, Canonica, Giorgo W., Cardona, Victoria, Carriazo, Ana M., Carr, Warner, Cartier, Christine, Casale, Thomas, Cecchi, Lorenzo, Cepeda Sarabia, Alfonso M., Chkhartishvili, Eka, Chu, Derek K., Cingi, Cemal, Colgan, Elaine, de Sousa, Jaime Correia, Courbis, Anne Lise, Custovic, Adnan, Cvetkosvki, Biljana, D’Amato, Gennaro, da Silva, Jane, Dantas, Carina, Dokic, Dejand, Dauvilliers, Yves, Dedeu, Antoni, De Feo, Giulia, Devillier, Philippe, Di Capua, Stefania, Dykewickz, Marc, Dubakiene, Ruta, Ebisawa, Motohiro, El-Gamal, Yaya, Eller, Esben, Emuzyte, Regina, Farrell, John, Fink-Wagner, Antjie, Fiocchi, Alessandro, Fontaine, Jean F., Gemicioğlu, Bilun, Schmid-Grendelmeir, Peter, Gamkrelidze, Amiran, Garcia-Aymerich, Judith, Gomez, Maximiliano, González Diaz, Sandra, Gotua, Maia, Guldemond, Nick A., Guzmán, Maria-Antonieta, Hajjam, Jawad, O’B Hourihane, John, Humbert, Marc, Iaccarino, Guido, Ierodiakonou, Despo, Ivancevich, Juan C., Joos, Guy, Jung, Ki-Suck, Jutel, Marek, Kaidashev, Igor, Kalayci, Omer, Kardas, Przemyslaw, Keil, Thomas, Khaitov, Mussa, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Kowalski, Marek L., Kritikos, Vicky, Kull, Inger, Leonardini, Lisa, Lieberman, Philip, Lipworth, Brian, Lodrup Carlsen, Karin C., Loureiro, Claudia C., Louis, Renaud, Mair, Alpana, Marien, Gert, Mahboub, Bassam, Malva, Joao, Manning, Patrick, De Manuel Keenoy, Esteban, Marshall, Gailen D., Masjedi, Mohamed R., Maspero, Jorge F., Mathieu-Dupas, Eve, Matricardi, Poalo M., Melén, Eric, Melo-Gomes, Elisabete, Meltzer, Eli O., Mercier, Jacques, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Moda, Giuliana, Mogica-Martinez, Maria-Dolores, Mohammad, Yousser, Montefort, Steve, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralf, Münter, Lars, Muraro, Antonella, Murray, Ruth, Naclerio, Robert, Napoli, Luigi, Namazova-Baranova, Leila, Neffen, Hugo, Nekam, Kristoff, Neou, Angelo, Novellino, Enrico, Nyembue, Dieudonné, O’Hehir, Robin, Ohta, Ken, Okubo, Kimi, Onorato, Gabrielle, Ouedraogo, Solange, Pali-Schöll, Isabella, Palkonen, Susanna, Panzner, Peter, Park, Hae-Sim, Pépin, Jean-Louis, Pereira, Ana-Maria, Pfaar, Oliver, Paulino, Ema, Phillips, Jim, Plavec, Davor, Popov, Ted A., Portejoie, Fabienne, Price, David, Prokopakis, Emmanuel P., Pugin, Benoit, Raciborski, Filip, Rajabian-Söderlund, Rojin, Reitsma, Sietze, Rodo, Xavier, Romano, Antonino, Rosario, Nelson, Rottem, Menahenm, Ryan, Dermot, Salimäki, Johanna, Sanchez-Borges, Mario M., Sisul, Juan-Carlos, Solé, Dirceu, Somekh, David, Sooronbaev, Talant, Sova, Milan, Spranger, Otto, Stellato, Cristina, Stelmach, Rafael, Suppli Ulrik, Charlotte, Thibaudon, Michel, To, Teresa, Todo-Bom, Ana, Tomazic, Peter V., Valero, Antonio A., Valenta, Rudolph, Valentin-Rostan, Marylin, van der Kleij, Rianne, Vandenplas, Olivier, Vezzani, Giorgio, Viart, Frédéric, Viegi, Giovanni, Wallace, Dana, Wagenmann, Martin, Wang, De Y., Waserman, Susan, Wickman, Magnus, Williams, Dennis M., Wong, Gary, Wroczynski, Piotr, Yorgancioglu, Arzu, Yusuf, Osman M., Zar, Heahter J., Zeng, Stéphane, Zernotti, Mario, Zhang, Luo, Zhong, Nan S., Zidarn, Mihaela, Bousquet, J., Hellings, P. W., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Aliberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Anto, J. M., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Bachert, C., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Basagana, X., Bateman, E. D., Bedolla-Barajas, M., Bedbrook, A., Bewick, M., Beghé, B., Bel, E. H., Bergmann, K. C., Benson, M., Bertorello, L., Białoszewski, A. Z., Bieber, T., Bialek, S., Bindslev-Jensen, C., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., the ARIA Study Group, the MASK Study Group, Briedis, Vitalis, uBibliorum, Yiallouros, Panayiotis K. [0000-0002-8339-9285], Costa, Elisio [0000-0003-1158-1480], Kritikos, Vicky [0000-0003-3955-0002], Gaga, Mina [0000-0002-9949-6012], Prokopakis, Emmanuel P. [0000-0002-1208-1990], Togias, Alkis [0000-0001-9009-5717], Erhola, Marina [0000-0002-1364-9023], Bosnic-Anticevich, Sinthia [0000-0001-5077-8329], Lourenço, Olga M. [0000-0002-8401-5976], Ierodiakonou, Despo [0000-0002-7862-2016], Health Services Management & Organisation (HSMO), Obstetrics & Gynecology, Universidade do Minho, Laboratoire de Génie Informatique et Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Bousquet, J. J., Schunemann, H. J., Togias, A., Erhola, M., Hellings, P. W., Zuberbier, T., Agache, I., Ansotegui, I. J., Anto, J. M., Bachert, C., Becker, S., Bedolla-Barajas, M., Bewick, M., Bosnic-Anticevich, S., Bosse, I., Boulet, L. P., Bourrez, J. M., Brusselle, G., Chavannes, N., Costa, E., Cruz, A. A., Czarlewski, W., Fokkens, W. J., Fonseca, J. A., Gaga, M., Haahtela, T., Illario, M., Klimek, L., Kuna, P., Kvedariene, V., Le, L. T. T., Larenas-Linnemann, D., Laune, D., Lourenco, O. M., Menditto, E., Mullol, J., Okamoto, Y., Papadopoulos, N., Pham-Thi, N., Picard, R., Pinnock, H., Roche, N., Roller-Wirnsberger, R. E., Rolland, C., Samolinski, B., Sheikh, A., Toppila-Salmi, S., Tsiligianni, I., Valiulis, A., Valovirta, E., Vasankari, T., Ventura, M. -T., Walker, S., Williams, S., Akdis, C. A., Annesi-Maesano, I., Arnavielhe, S., Basagana, X., Bateman, E., Bedbrook, A., Bennoor, K. S., Benveniste, S., Bergmann, K. C., Bialek, S., Billo, N., Bindslev-Jensen, C., Bjermer, L., Blain, H., Bonini, M., Bonniaud, P., Bouchard, J., Briedis, V., Brightling, C. E., Brozek, J., Buhl, R., Buonaiuto, R., Canonica, G. W., Cardona, V., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Cecchi, L., Cepeda Sarabia, A. M., Chkhartishvili, E., Chu, D. K., Cingi, C., Colgan, E., De Sousa, J. C., Courbis, A. L., Custovic, A., Cvetkosvki, B., Damato, G., Da Silva, J., Dantas, C., Dokic, D., Dauvilliers, Y., Dedeu, A., De Feo, G., Devillier, P., Di Capua, S., Dykewickz, M., Dubakiene, R., Ebisawa, M., El-Gamal, Y., Eller, E., Emuzyte, R., Farrell, J., Fink-Wagner, A., Fiocchi, A., Fontaine, J. F., Gemicioglu, B., Schmid-Grendelmeir, P., Gamkrelidze, A., Garcia-Aymerich, J., Gomez, M., Diaz, S. G., Gotua, M., Guldemond, N. A., Guzman, M. -A., Hajjam, J., O'Hourihane, J. B., Humbert, M., Iaccarino, G., Ierodiakonou, D., Ivancevich, J. C., Joos, G., Jung, K. -S., Jutel, M., Kaidashev, I., Kalayci, O., Kardas, P., Keil, T., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M. L., Kritikos, V., Kull, I., Leonardini, L., Lieberman, P., Lipworth, B., Lodrup Carlsen, K. C., Loureiro, C. C., Louis, R., Mair, A., Marien, G., Mahboub, B., Malva, J., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matricardi, P. M., Melen, E., Melo-Gomes, E., Meltzer, E. O., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. -D., Mohammad, Y., Montefort, S., Monti, R., Morais-Almeida, M., Mosges, R., Munter, L., Muraro, A., Murray, R., Naclerio, R., Napoli, L., Namazova-Baranova, L., Neffen, H., Nekam, K., Neou, A., Novellino, E., Nyembue, D., O'Hehir, R., Ohta, K., Okubo, K., Onorato, G., Ouedraogo, S., Pali-Scholl, I., Palkonen, S., Panzner, P., Park, H. -S., Pepin, J. -L., Pereira, A. -M., Pfaar, O., Paulino, E., Phillips, J., Plavec, D., Popov, T. A., Portejoie, F., Price, D., Prokopakis, E. P., Pugin, B., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Rodo, X., Romano, A., Rosario, N., Rottem, M., Ryan, D., Salimaki, J., Sanchez-Borges, M. M., Sisul, J. -C., Sole, D., Somekh, D., Sooronbaev, T., Sova, M., Spranger, O., Stellato, C., Stelmach, R., Ulrik, C. S., Thibaudon, M., To, T., Todo-Bom, A., Tomazic, P. V., Valero, A. A., Valenta, R., Valentin-Rostan, M., Van Der Kleij, R., Vandenplas, O., Vezzani, G., Viart, F., Viegi, G., Wallace, D., Wagenmann, M., Wang, D. Y., Waserman, S., Wickman, M., Williams, D. M., Wong, G., Wroczynski, P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zeng, S., Zernotti, M., Zhang, L., Zhong, N. S., Zidarn, M., UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie
Subjects: Allergy, IMPACT, Respiratory Medicine and Allergy, ARIA Study Group, Health care transformation, Care pathways, Rhinitis, ARIA, MASK, POLLAR, Review, GUIDELINES, Medical and Health Sciences, PATIENT-CARE, 0302 clinical medicine, immune system diseases, 11. Sustainability, Health care, Medicine and Health Sciences, Outras Ciências Médicas [Ciências Médicas], Immunology and Allergy, Medicine, 030212 general & internal medicine, mHealth, health care economics and organizations, Lungmedicin och allergi, Rhinitis, Self-management, 616.2 [udc], Environmental exposure, POLLAR, 3. Good health, CHRONIC RESPIRATORY-DISEASES, Care pathways, HEALTH, Life Sciences & Biomedicine, Pulmonary and Respiratory Medicine, SEASONAL ALLERGIC RHINITIS, medicine.medical_specialty, animal structures, MASK, Health care transformation, EUROPEAN INNOVATION PARTNERSHIP, ARIA, Immunology, Health literacy, 03 medical and health sciences, INTERMITTENT, BUDESONIDE-FORMOTEROL, As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement, Air pollutants, adverse effects, Air pollution, Asthma, physiopathology, physiopathology [In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body], Patient participation, SELF-MANAGEMENT, MASK Study Group, Ciências Médicas::Outras Ciências Médicas, udc:616.2, Care pathway, Science & Technology, business.industry, RC581-607, medicine.disease, respiratory tract diseases, Integrated care, 030228 respiratory system, 13. Climate action, Family medicine, Immunologic diseases. Allergy, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted “patient activation”, (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement., Partly funded by POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), and ARIA.
Published: 2019

41. Европейский стратегический форум по аллергическим болезням : определение приоритетов научных проблем и финансирования в отношении аллергии и бронхиальной астмы и необходимость трансляционных исследований

Author: Agache, Ioana, Annesi-Maesano, Isabella, Bonertz, Andreas, Branca, Francesco, Cant, Andrew, Fras, Zlatko, Ingenrieth, Frank, Namazova-Baranova, Leyla, Odemyr, Mikaela, Spanevello, Antonio, Vieths, Stefan, Yorgancioglu, Arzu, Alvaro-Lozano, Montserat, Hernandez, Domingo Barber, Chivato, Tomas, Del Giacco, Stefano, Diamant, Zuzana, Eguiluz-Gracia, Ibon, van Wijk, Roy Gert, Gevaert, Philippe, Graessel, Anke, Hellings, Peter, Hoffmann-Sommergruber, Karin, Jutel, Marek, Lau, Susanne, Lauerma, Antti, Olaguibel, Jose Maria, O'Mahony, Liam, Ozdemir, Cevdet, Palomares, Oscar, Pfaar, Oliver, Sastre, Joaquin, Scadding, Glennis, Schmidt-Weber, Carsten, Schmid-Grendelmeier, Peter, Shamji, Mohamed, Skypala, Isabel, Spinola, Monica, Spranger, Otto, Torres, Maria, Vereda, Andrea, Bonini, Sergio, Helsingfors universitet, Kliniken för hud- och könssjukdomar, Universitetets ledning, and HUS Inflammationscentrum
Subjects: 3121 General medicine, internal medicine and other clinical medicine
Abstract: The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients' organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
Published: 2019

42. MOESM1 of Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

Author: J. Bousquet, SchĂźnemann, Holger, Togias, Alkis, Erhola, Marina, Hellings, Peter, Zuberbier, Torsten, Agache, Ioana, Ansotegui, Ignacio, Anto, Josep, Bachert, Claus, Becker, Sven, Bedolla-Barajas, Martin, Bewick, Michael, Sinthia Bosnic-Anticevich, Bosse, Isabelle, Boulet, Louis, Bourrez, Jean, Brusselle, Guy, Chavannes, Niels, Elisio Costa, Cruz, Alvaro, Wienczyslawa Czarlewski, Fokkens, Wytske, Joao Fonseca, Gaga, Mina, Tari Haahtela, Illario, Maddalena, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, L. Le, Larenas-Linnemann, Desiree, Laune, Daniel, LourenĂ§O, Olga, Menditto, Enrica, Joaquin Mullol, Yashitaka Okamoto, Papadopoulos, Nikos, NhĂ˘N Pham-Thi, Picard, Robert, Pinnock, Hilary, Roche, Nicolas, Roller-Wirnsberger, Regina, Rolland, Christine, Boleslaw Samolinski, Sheikh, Aziz, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Arunas Valiulis, Valovirta, Erkka, Vasankari, Tuula, Maria-Teresa Ventura, Walker, Samantha, Williams, Sian, Akdis, Cezmi, Annesi-Maesano, Isabella, Arnavielhe, Sylvie, Basagana, Xavier, Bateman, Eric, Bedbrook, Anna, K. Bennoor, Benveniste, Samuel, Bergmann, Karl, Slawomir Bialek, Billo, Nils, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Bonini, Mateo, Bonniaud, Philippe, Bouchard, Jacques, Briedis, Vitalis, Brightling, Christofer, Brozek, Jan, Buhl, Roland, Buonaiuto, Roland, Giorgo Canonica, Cardona, Victoria, Carriazo, Ana, Carr, Warner, Cartier, Christine, Casale, Thomas, Cecchi, Lorenzo, Sarabia, Alfonso Cepeda, Chkhartishvili, Eka, Chu, Derek, Cingi, Cemal, Colgan, Elaine, Sousa, Jaime, Courbis, Anne, Custovic, Adnan, Cvetkosvki, Biljana, DâAmato, Gennaro, Silva, Jane, Dantas, Carina, Dejand Dokic, Dauvilliers, Yves, Dedeu, Antoni, Feo, Giulia, Devillier, Philippe, Capua, Stefania, Dykewickz, Marc, Dubakiene, Ruta, Ebisawa, Motohiro, Yaya El-Gamal, Eller, Esben, Emuzyte, Regina, Farrell, John, Antjie Fink-Wagner, Fiocchi, Alessandro, Fontaine, Jean, Bilun GemicioÄLu, Schmid-Grendelmeir, Peter, Gamkrelidze, Amiran, Garcia-Aymerich, Judith, Gomez, Maximiliano, Diaz, Sandra GonzĂĄlez, Gotua, Maia, Guldemond, Nick, Maria-Antonieta GuzmĂĄn, Hajjam, Jawad, Hourihane, John OâB, Humbert, Marc, Iaccarino, Guido, Despo Ierodiakonou, Ivancevich, Juan, Joos, Guy, Ki-Suck Jung, Jutel, Marek, Kaidashev, Igor, Kalayci, Omer, Przemyslaw Kardas, Keil, Thomas, Mussa Khaitov, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Kowalski, Marek, Kritikos, Vicky, Kull, Inger, Leonardini, Lisa, Lieberman, Philip, Lipworth, Brian, Carlsen, Karin Lodrup, Loureiro, Claudia, Louis, Renaud, Alpana Mair, Marien, Gert, Mahboub, Bassam, Joao Malva, Manning, Patrick, Keenoy, Esteban Manuel, Gailen Marshall, Masjedi, Mohamed, Maspero, Jorge, Mathieu-Dupas, Eve, Poalo Matricardi, MelĂŠn, Eric, Melo-Gomes, Elisabete, Meltzer, Eli, Mercier, Jacques, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Moda, Giuliana, Maria-Dolores Mogica-Martinez, Yousser Mohammad, Montefort, Steve, Monti, Ricardo, Morais-Almeida, Mario, MĂśsges, Ralf, MĂźnter, Lars, Muraro, Antonella, Murray, Ruth, Naclerio, Robert, Napoli, Luigi, Namazova-Baranova, Leila, Neffen, Hugo, Kristoff Nekam, Neou, Angelo, Novellino, Enrico, DieudonnĂŠ Nyembue, OâHehir, Robin, Ohta, Ken, Okubo, Kimi, Onorato, Gabrielle, Ouedraogo, Solange, Pali-SchĂśll, Isabella, Palkonen, Susanna, Panzner, Peter, Hae-Sim Park, Jean-Louis PĂŠpin, Ana-Maria Pereira, Pfaar, Oliver, Paulino, Ema, Phillips, Jim, Plavec, Davor, Popov, Ted, Portejoie, Fabienne, Price, David, Prokopakis, Emmanuel, Benoit Pugin, Raciborski, Filip, Rojin Rajabian-SĂśderlund, Reitsma, Sietze, Rodo, Xavier, Romano, Antonino, Rosario, Nelson, Menahenm Rottem, Ryan, Dermot, SalimĂ¤Ki, Johanna, Sanchez-Borges, Mario, Juan-Carlos Sisul, Dirceu SolĂŠ, Somekh, David, Talant Sooronbaev, Sova, Milan, Spranger, Otto, Stellato, Cristina, Stelmach, Rafael, Ulrik, Charlotte Suppli, Thibaudon, Michel, To, Teresa, Todo-Bom, Ana, Tomazic, Peter, Valero, Antonio, Valenta, Rudolph, Valentin-Rostan, Marylin, Kleij, Rianne, Vandenplas, Olivier, Vezzani, Giorgio, FrĂŠdĂŠric Viart, Viegi, Giovanni, Wallace, Dana, Wagenmann, Martin, Wang, De, Waserman, Susan, Wickman, Magnus, Williams, Dennis, Wong, Gary, Wroczynski, Piotr, Yiallouros, Panayiotis, Yorgancioglu, Arzu, Yusuf, Osman, Heahter Zar, StĂŠphane Zeng, Zernotti, Mario, Zhang, Luo, Zhong, Nan, and Zidarn, Mihaela
Abstract: Additional file 1. The MASK Study Group.
Published: 2019
Full Text: View/download PDF

43. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

Author: Bousquet, J. Jean Schunemann, Holger J. Togias, Alkis and Erhola, Marina Hellings, Peter W. Zuberbier, Torsten Agache, Ioana Ansotegui, Ignacio J. Anto, Josep M. Bachert, Claus and Becker, Sven Bedolla-Barajas, Martin Bewick, Michael and Bosnic-Anticevich, Sinthia Bosse, Isabelle Boulet, Louis P. and Bourrez, Jean Marc Brusselle, Guy Chavannes, Niels Costa, Elisio Cruz, Alvaro A. Czarlewski, Wienczyslawa Fokkens, Wytske J. Fonseca, Joao A. Gaga, Mina Haahtela, Tari and Illario, Maddalena Klimek, Ludger Kuna, Piotr Kvedariene, Violeta Le, L. T. T. Larenas-Linnemann, Desiree Laune, Daniel Lourenco, Olga M. Menditto, Enrica Mullo, Joaquin and Okamoto, Yashitaka Papadopoulos, Nikos Nhan Pham-Thi Picard, Robert Pinnock, Hilary Roche, Nicolas Roller-Wirnsberger, Regina E. Rolland, Christine Samolinski, Boleslaw Sheikh, Aziz Toppila-Salmi, Sanna Tsiligianni, Ioanna Valiulis, Arunas Valovirta, Erkka Vasankari, Tuula Ventura, Maria-Teresa Walker, Samantha Williams, Sian Akdis, Cezmi A. and Annesi-Maesano, Isabella Arnavielhe, Sylvie Basagana, Xavier and Bateman, Eric Bedbrook, Anna Bennoor, K. S. Benveniste, Samuel Bergmann, Karl C. Bia, Slawomir Billo, Nils and Bindslev-Jensen, Carsten Bjermer, Leif Blain, Hubert Bonini, Mateo Bonniaud, Philippe Bouchard, Jacques Briedis, Vitalis and Brightling, Christofer E. Brozek, Jan Buhl, Roland and Buonaiuto, Roland Canonica, Giorgo W. Cardona, Victoria and Carriazo, Ana M. Carr, Warner Cartier, Christine Casale, Thomas Cecchi, Lorenzo Cepeda Sarabia, Alfonso M. and Chkhartishvili, Eka Chu, Derek K. Cingi, Cemal Colgan, Elaine de Sousa, Jaime Correia Courbis, Anne Lise Custovic, Adnan Cvetkosvki, Biljana D'Amato, Gennaro da Silva, Jane and Dantas, Carina Dokic, Dejand Dauvilliers, Yves Dedeu, Antoni De Feo, Giulia Devillier, Philippe Di Capua, Stefania and Dykewickz, Marc Dubakiene, Ruta Ebisawa, Motohiro and El-Gamal, Yaya Eller, Esben Emuzyte, Regina Farrell, John and Fink-Wagner, Antjie Fiocchi, Alessandro Fontaine, Jean F. and Gemicioglu, Bilun Schmid-Grendelmeir, Peter Gamkrelidze, Amiran Garcia-Aymerich, Judith Gomez, Maximiliano Gonzalez Diaz, Sandra Gotua, Maia Guldemond, Nick A. Guzman, Maria-Antonieta Hajjam, Jawad Hourihane, John O'B Humbert, Marc Iaccarino, Guido Ierodiakonou, Despo Ivancevich, Juan C. Joos, Guy Jung, Ki-Suck Jutel, Marek Kaidashev, Igor and Kalayci, Omer Kardas, Przemyslaw Keil, Thomas Khaitov, Mussa Khaltaev, Nikolai Kleine-Tebbe, Jorg Kowalski, Marek L. Kritikos, Vicky Kull, Inger Leonardini, Lisa and Lieberman, Philip Lipworth, Brian Carlsen, Karin C. Lodrup and Loureiro, Claudia C. Louis, Renaud Mair, Alpana Marien, Gert and Mahboub, Bassam Malva, Joao Manning, Patrick Keenoy, Esteban De Manuel Marshall, Gallen D. Masjedi, Mohamed R. and Maspero, Jorge F. Mathieu-Dupas, Eve Matricardi, Poalo M. and Melen, Eric Melo-Gomes, Elisabete Meltzer, Eli O. Mercier, Jacques Miculinic, Neven Mihaltan, Florin Milenkovic, Branislava Moda, Giuliana Mogica-Martinezl, Maria-Dolores and Mohammad, Yousser Montefort, Steve Monti, Ricardo and Morais-Almeida, Mario Moesges, Raft Munter, Lars Muraro, Antonella Murray, Ruth Naclerio, Robert Napoli, Luigi and Namazova-Baranova, Leila Neffen, Hugo Nekam, Kristoff Neou, Angelo Novellino, Enrico Nyembue, Dieudonne O'Hehir, Robin and Ohta, Ken Okubo, Kimi Onorato, Gabrielle Ouedraogo, Solange Pali-Schoell, Isabella Palkonen, Susanna Panzner, Peter Park, Hae-Sim Pepin, Jean-Louis Pereira, Ana-Maria and Pfaar, Oliver Paulino, Ema Phillips, Jim Plavec, Davor and Popov, Ted A. Portejoie, Fabienne Price, David Prokopakis, Emmanuel P. Pugin, Benoit Raciborski, Filip and Rajabian-Soderlund, Rojin Reitsma, Sietze Rodo, Xavier and Romano, Antonino Rosario, Nelson Rottem, Menahenm Ryan, Dermot Salimaki, Johanna Sanchez-Borges, Mario M. Sisul, Juan-Carlos Sole, Dirceu Somekh, David Sooronbaev, Talant and Sova, Milan Spranger, Otto Stellato, Cristina Stelmach, Rafael Ulrik, Charlotte Suppli Thibaudon, Michel To, Teresa and Todo-Bom, Ana Tomazic, V, Peter Valero, Antonio A. and Valenta, Rudolph Valentin-Rostan, Marylin van der Kleij, Rianne and Vandenplas, Olivier Vezzani, Giorgio Viart, Frederic and Vieg, Giovanni Wallace, Dana Wagenmann, Martin Wang, De Y. and Waserman, Susan Wickman, Magnus Williams, Dennis M. and Wong, Gary Wroczynski, Piotr Yiallouros, Panayiotis K. and Yorgancioglu, Arzu Yusuf, Osman M. Zar, Heahter J. Zeng, Stephane Zernotti, Mario Zhang, Luo Zhong, Nan S. and Zidarn, Mihaela ARIA Study Grp MASK Study Grp
Abstract: Background In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted “patient activation”, (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Sante as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
Published: 2019

44. Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma

Author: Agache, Ioana, Miller, Rachel, Gern, James E., Hellings, Peter W., Jutel, Marek, Muraro, Antonella, Phipatanakul, Wanda, Quirce, Santiago, Peden, David, and Ear, Nose and Throat
Subjects: 0301 basic medicine, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Environmental health, 030228 respiratory system, Allergy, Allergy--Environmental aspects, FOS: Clinical medicine, Medicine, Asthma--Environmental aspects, Asthma
Abstract: Exposome research can improve the understanding of the mechanistic connections between exposures and health to help mitigate adverse health outcomes across the life span. The exposomic approach provides a risk profile instead of single predictors and thus is particularly applicable to allergic diseases and asthma. Under the PRACTALL collaboration between the European Academy of Allergy and Clinical Immunology (EAACI) and the American Academy of Allergy, Asthma, and Immunology (AAAAI), we evaluated the current concepts and the unmet needs on the role of the exposome in allergic diseases and asthma.
Published: 2018
Full Text: View/download PDF

45. Alergie na jady owadów

Author: Cichocka-Jarosz, Ewa, Gajewski, Piotr, and Jutel, Marek
Published: 2018

46. Alergie na jady owadów

Author: Jutel, Marek and Cichocka-Jarosz, Ewa
Published: 2018

47. Validation of the Global Allergy and Asthma European Network (GA 2 LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber

Author: Zuberbier , Torsten, Abelson , Mark, Akdis , Cezmi, Bachert , Claus, Berger , Uwe, Bindslev-Jensen , Carsten, Boelke , Georg, Bousquet , Jean, Canonica , Giorgio Walter, Casale , Thomas, Jutel , Marek, Kowalski , Marek, Madonini , Enzo, Papadopoulos , Nikolaos, Pfaar , Oliver, Sehlinger , Torsten, Bergmann , Karl-Christian, European Union Network of Excellence in Allergy and Asthma , Global Allergy and Asthma European Network (GA(2)LEN), and Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier )
Subjects: validation, Global Allergy and Asthma European Network (GA(2)LEN), [ SDV.IMM.ALL ] Life Sciences [q-bio]/Immunology/Allergology, grasses, placebo, Allergy trial, environmental exposure chamber
Abstract: International audience; BACKGROUND:Field clinical trials of pollen allergy are affected by the impossibility of predicting and determining individual allergen exposure because of many factors (eg, pollen season, atmospheric variations, pollutants, and lifestyles). Environmental exposure chambers, delivering a fixed amount of allergen in a controlled environmental setting, can overcome these limitations. Environmental exposure chambers are currently already used in phase 2, 3, and even 4 trials. Unfortunately, few chambers exist in the world, and this makes it difficult to perform large, multicenter clinical trials. The new Global Allergy and Asthma European Network (GA2LEN) mobile exposure chamber is a step forward because the mobility of the chamber makes it convenient for patients to participate in clinical testing.OBJECTIVE:This study was made to validate the reproducibility, sensitivity, and specificity of the results obtained in the new GA2LEN chamber.METHODS:Seventy-two adult patients (19-61 years old) with allergic rhinitis with or without asthma caused by grass pollen were included in different clinical validation tests. Total symptom scores and total nasal symptom scores were recorded at time zero (0) and every 10 minutes during exposures, along with nasal and respiratory parameters.RESULTS:Exposure tests confirmed the reproducibility between subsequent runs and the sensitivity (P < .00001 vs patients exposed to placebo) and specificity (very low score in nonallergic subjects) in the GA2LEN chamber. No adverse reactions were recorded during the tests.CONCLUSIONS:The mobility of the GA2LEN chamber provides a new, potentially effective, and safe way of generating reliable data in allergy multicenter clinical trials.
Published: 2017

48. Allergen immunotherapy for allergic asthma: protocol for a systematic review (vol 6, 5, 2016)

Author: Dhami, Sangeeta Nurmatov, Ulugbek Agache, Ioana Lau, Susanne and Muraro, Antonella Jutel, Marek Roberts, Graham Akdis, Cezmi Bonini, Matteo Calderon, Moises Casale, Thomas and Cavkaytar, Ozlem Cox, Linda Demoly, Pascal Flood, Breda and Hamelmann, Eckard Izuhara, Kenji Kalayci, Omer Kleine-Tebbe, Jorg Nieto, Antonio Papadopoulos, Nikolaos Pfaar, Oliver and Rosenwasser, Lanny Ryan, Dermot Schmidt-Weber, Carsten and Szefler, Stan Wahn, Ulrich van Wijk, Roy-Gerth Wilkinson, Jamie Sheikh, Aziz
Published: 2017

49. MOESM4 of Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study

Author: Boelke, Georg, Berger, Uwe, Karl-Christian Bergmann, Bindslev-Jensen, Carsten, Bousquet, Jean, Gildemeister, Julia, Jutel, Marek, Pfaar, Oliver, Sehlinger, Torsten, and Zuberbier, Torsten
Abstract: Additional file 4: Figure S1. Reduction of PNIF during exposure with birch pollen in the GA²LEN chamber. PNIF development during exposure with Betula pendula. Every challenge to birch pollen got pooled into one active group and only those runs were included where a TNSS greater than 2 points was reported on at least two symptom check cards throughout the whole challenge. A hash marks a reduction compared to baseline p
Published: 2017
Full Text: View/download PDF

50. MOESM6 of Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study

Author: Boelke, Georg, Berger, Uwe, Karl-Christian Bergmann, Bindslev-Jensen, Carsten, Bousquet, Jean, Gildemeister, Julia, Jutel, Marek, Pfaar, Oliver, Sehlinger, Torsten, and Zuberbier, Torsten
Abstract: Additional file 6: Appendix S1. Comparison between the different allergens.
Published: 2017
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

67 results on '"Jutel, Marek"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources